Executive summary. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI) | Enfermedades Infecciosas y Microbiología Clínica

array:23 ["pii" => "S0213005X15001433" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2015.03.020" "estado" => "S300" "fechaPublicacion" => "2015-12-01" "aid" => "1328" "copyright" => "Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "copyrightAnyo" => "2015" "documento" => "article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Enferm Infecc Microbiol Clin. 2015;33:680-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2695 "formatos" => array:3 [ "EPUB" => 12 "HTML" => 1721 "PDF" => 962 ] ] "itemSiguiente" => array:18 [ "pii" => "S0213005X15000774" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2015.02.008" "estado" => "S300" "fechaPublicacion" => "2015-12-01" "aid" => "1295" "copyright" => "Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Enferm Infecc Microbiol Clin. 2015;33:688-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3713 "formatos" => array:3 [ "EPUB" => 18 "HTML" => 2919 "PDF" => 776 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "Diagnóstico a primera vista" "titulo" => "Nódulos fluctuantes en el cuero cabelludo de un niño" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "688" "paginaFinal" => "689" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Fluctuating nodules on the scalp of a child" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1046 "Ancho" => 1500 "Tamanyo" => 354983 ] ] "descripcion" => array:1 [ "es" => "A, B y C. Cuero cabelludo con múltiples nódulos eritematosos, fluctuantes, con áreas alopécicas en su superficie, acompañados de abundantes pústulas. D. Cultivo de hongos, en el que se observan colonias de color blanco-amarillento. E. Preparación teñida con azul de lactofenol, en la que se observan hifas septadas con macroconidias de extremos aguzados." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juan Manríquez, Sergio Niklitschek" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Juan" "apellidos" => "Manríquez" ] 1 => array:2 [ "nombre" => "Sergio" "apellidos" => "Niklitschek" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X15000774?idApp=UINPBA00004N" "url" => "/0213005X/0000003300000010/v1_201512110028/S0213005X15000774/v1_201512110028/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0213005X15001470" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2015.03.024" "estado" => "S300" "fechaPublicacion" => "2015-12-01" "aid" => "1332" "copyright" => "Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Enferm Infecc Microbiol Clin. 2015;33:679.e1-679.e21" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 9425 "formatos" => array:3 [ "EPUB" => 16 "HTML" => 8064 "PDF" => 1345 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Consensus statement" "titulo" => "Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI)" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "679.e1" "paginaFinal" => "679.e21" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento de la infección del tracto urinario en los receptores de trasplantes de órganos sólidos: Declaración de consenso del Grupo de Estudio de Infección en receptores de trasplantes (GESITRA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y la Red Española de Investigación en Patología Infecciosa (REIPI)" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Elisa Vidal, Carlos Cervera, Elisa Cordero, Carlos Armiñanzas, Jordi Carratalá, José Miguel Cisneros, M. Carmen Fariñas, Francisco López-Medrano, Asunción Moreno, Patricia Muñoz, Julia Origüen, Núria Sabé, Maricela Valerio, Julián Torre-Cisneros" "autores" => array:16 [ 0 => array:2 [ "nombre" => "Elisa" "apellidos" => "Vidal" ] 1 => array:2 [ "nombre" => "Carlos" "apellidos" => "Cervera" ] 2 => array:2 [ "nombre" => "Elisa" "apellidos" => "Cordero" ] 3 => array:2 [ "nombre" => "Carlos" "apellidos" => "Armiñanzas" ] 4 => array:2 [ "nombre" => "Jordi" "apellidos" => "Carratalá" ] 5 => array:2 [ "nombre" => "José Miguel" "apellidos" => "Cisneros" ] 6 => array:2 [ "nombre" => "M. Carmen" "apellidos" => "Fariñas" ] 7 => array:2 [ "nombre" => "Francisco" "apellidos" => "López-Medrano" ] 8 => array:2 [ "nombre" => "Asunción" "apellidos" => "Moreno" ] 9 => array:2 [ "nombre" => "Patricia" "apellidos" => "Muñoz" ] 10 => array:2 [ "nombre" => "Julia" "apellidos" => "Origüen" ] 11 => array:2 [ "nombre" => "Núria" "apellidos" => "Sabé" ] 12 => array:2 [ "nombre" => "Maricela" "apellidos" => "Valerio" ] 13 => array:2 [ "nombre" => "Julián" "apellidos" => "Torre-Cisneros" ] 14 => array:1 [ "colaborador" => "Study Group of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases, Clinical Microbiology (SEIMC)" ] 15 => array:1 [ "colaborador" => "Spanish Network for Research in Infectious Diseases (REIPI)" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X15001470?idApp=UINPBA00004N" "url" => "/0213005X/0000003300000010/v1_201512110028/S0213005X15001470/v1_201512110028/en/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "Consensus statement" "titulo" => "Executive summary. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI)" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "680" "paginaFinal" => "687" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Elisa Vidal, Carlos Cervera, Elisa Cordero, Carlos Armiñanzas, Jordi Carratalá, José Miguel Cisneros, M. Carmen Fariñas, Francisco López-Medrano, Asunción Moreno, Patricia Muñoz, Julia Origüen, Núria Sabé, Maricela Valerio, Julián Torre-Cisneros" "autores" => array:15 [ 0 => array:4 [ "nombre" => "Elisa" "apellidos" => "Vidal" "email" => array:1 [ 0 => "vidal.elisa@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "◊" "identificador" => "fn1" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Carlos" "apellidos" => "Cervera" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "◊" "identificador" => "fn1" ] ] ] 2 => array:3 [ "nombre" => "Elisa" "apellidos" => "Cordero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Carlos" "apellidos" => "Armiñanzas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "Jordi" "apellidos" => "Carratalá" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "José Miguel" "apellidos" => "Cisneros" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 6 => array:3 [ "nombre" => "M. Carmen" "apellidos" => "Fariñas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 7 => array:3 [ "nombre" => "Francisco" "apellidos" => "López-Medrano" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] ] ] 8 => array:3 [ "nombre" => "Asunción" "apellidos" => "Moreno" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 9 => array:3 [ "nombre" => "Patricia" "apellidos" => "Muñoz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "g" "identificador" => "aff0035" ] ] ] 10 => array:3 [ "nombre" => "Julia" "apellidos" => "Origüen" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] ] ] 11 => array:3 [ "nombre" => "Núria" "apellidos" => "Sabé" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 12 => array:3 [ "nombre" => "Maricela" "apellidos" => "Valerio" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "g" "identificador" => "aff0035" ] ] ] 13 => array:3 [ "nombre" => "Julián" "apellidos" => "Torre-Cisneros" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 14 => array:1 [ "colaborador" => "Study Group of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases, Clinical Microbiology (SEIMC), Spanish Network for Research in Infectious Diseases (REIPI)" ] ] "afiliaciones" => array:7 [ 0 => array:3 [ "entidad" => "Unidad Clínica de Gestión de Enfermedades Infecciosas, Instituto Maimónides de Investigación en Biomedicina de Córdoba, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Enfermedades Infecciosas, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Unidad Clínica de Gestión de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Unidad de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Servicio de Enfermedades Infecciosas, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Universidad de Barcelona, Barcelona, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Instituto de Investigación Biomédica 12 de Octubre, Departamento de Medicina, Universidad Complutense, Madrid, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Departamento de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Executive summary. Abordaje de la infección urinaria en receptores de trasplante de órgano sólido: documento de consenso del Grupo de Estudio de la Infección en Receptores de Trasplante (GESITRA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y la Red Española para el Estudio de Patología Infecciosa (REIPI)" ] ] "textoCompleto" => "IntroductionThe use of solid organ transplantation (SOT) has been established as accepted therapy for end-stage disease of the kidneys, liver, heart, and lungs for nearly 30 years. Intestinal and pancreas transplantation are also generally available but are provided on a more limited basis.Infections remain a major cause of morbidity and mortality in transplant recipients. Urinary tract infections (UTI) are one of the most common infections in SOT, with a high prevalence, reaching 75% in some series involving kidney recipients. Experienced SOT researchers and clinicians have developed and implemented this consensus document in support of the optimal management of these patients.The target population of this document are adults receiving SOT. The intended guideline audience is physicians involved in the care of SOT recipients (including primary care physicians). Here we report a consensus with the objective of assessing the overall available evidence and to propose recommendations on the following key issues:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">1.Definitions.</li><li class="elsevierStyleListItem" id="lsti0010">2.Epidemiology and risk factors for UTI in SOT recipients.</li><li class="elsevierStyleListItem" id="lsti0015">3.Should SOT recipients receive primary prophylaxis for UTI?</li><li class="elsevierStyleListItem" id="lsti0020">4.What should be the management of asymptomatic bacteriuria in SOT recipients?</li><li class="elsevierStyleListItem" id="lsti0025">5.What is the best empirical treatment of UTI in SOT recipients?</li><li class="elsevierStyleListItem" id="lsti0030">6.What is the best definitive treatment of UTI in SOT recipients?</li><li class="elsevierStyleListItem" id="lsti0035">7.How long should SOT recipients receive antibiotics for a UTI?</li><li class="elsevierStyleListItem" id="lsti0040">8.What should be the management of UTI caused by Candida spp. in SOT recipients?</li><li class="elsevierStyleListItem" id="lsti0045">9.What should be the diagnostic–therapeutic management of recurrent UTI in SOT recipients?</li><li class="elsevierStyleListItem" id="lsti0050">10.What role does UTI play in kidney graft rejection or dysfunction?</li><li class="elsevierStyleListItem" id="lsti0055">11.Antimicrobial and immunosuppressant interactions.</li></ul>MethodsWe conducted a systematic review to assess the management of UTI in SOT recipients. Data for this document were identified through a search of PubMed and references from relevant articles using the search terms “transplant” and “urinary tract infection”. The search criteria included articles in English that involved human participants. We selected and revised a total of 3043 articles from 1968 to June 2014.The evidence level based on the available literature is given for each recommendation to assess the strength of the evidence for risk and benefits of the procedure. This article was written in accordance with international recommendations on consensus statements (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>) and the recommendations of the Appraisal of Guidelines for Research and Evaluation II (AGREE II). The authors met twice to discuss the consensus and establish formal recommendations. The coordinators and authors agree on the content and conclusions. The consensus statement was sent to the 96 members of GESITRA for external revision of the manuscript. The board of directors of GESITRA will designate the coordinators to update the statements within 5 years. The full version of the consensus document of this executive summary is available at Ref. <a class="elsevierStyleCrossRef" href="#bib0005">1</a>.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>DefinitionsBacteriuriaBacteriuria is defined according to the criteria proposed by the Infectious Diseases Society of America guidelines. For asymptomatic women, bacteriuria is defined as 2 consecutive voided urine specimens with isolation of the same bacterial strain in quantitative counts ≥105 colony-forming units (cfu)/ml. A single, clean-catch voided urine specimen with 1 bacterial species isolated in a quantitative count ≥105cfu/ml identifies bacteriuria in men. A single catheterized urine specimen with 1 bacterial species isolated in a quantitative count ≥102cfu/ml identifies bacteriuria in women or men. Asymptomatic bacteriuria (AB) is defined by the presence of bacteriuria in the absence of any symptoms of lower or upper UTI.CystitisCystitis is defined by the presence of bacteriuria and clinical manifestations such as dysuria, frequency, or urinary urgency in the absence of pyelonephritis criteria.PyelonephritisPyelonephritis is defined by the simultaneous presence of a urine bacteria count ≥105cfu/ml and/or bacteremia and fever with one or more of the following four categories: costovertebral angle pain (if native kidney involved), renal allograft tenderness (if transplanted kidney involved), chills, criteria for cystitis (bacteriuria and clinical manifestations such as dysuria, frequency, or urinary urgency).ReinfectionReinfection is defined by a new episode of infection with the isolation of bacterium other than the one that caused the previous infection or the same bacteria with a different antibiotic sensitivity pattern.RelapseRelapse is defined as the isolation of the same microorganism that caused the preceding infection, with the same antibiotic sensitivity pattern, in a urine culture obtained ≥2 weeks after finishing the previous treatment.Recurrent infectionRecurrent infection is commonly defined as three or more episodes of symptomatic UTIs over a 12-month period or two episodes in the previous six months.Complicated urinary tract infectionA complicated UTI is defined as an infection that is associated with structural or functional abnormalities of the genitourinary tract, or the presence of an underlying disease that increases the risk of acquiring an infection or of failing therapy.ProstatitisProstatitis is characterized by discomfort referred to the lower urogenital and perineal and/or ejaculatory discomfort or sexual dysfunction. Acute bacterial prostatitis is presented as fever and chills accompanied by urinary symptoms such as dysuria, frequency, and perineal pain. Chronic bacterial prostatitis has a more prolonged course, usually of at least 3 months. This is usually related to or the result of recurrent urinary infection, or may be a complication of acute prostatitis that is not properly cured, urethritis, or epididymitis. The disease can occur continuously or episodically. The symptoms are milder than in acute prostatitis and sometimes imperceptible. The most common symptoms are perineal or pelvic pain, low back pain, testicular pain, and discomfort when urinating or ejaculating.The classification of patients with prostatitis depends on the bacteriological study of lower urinary tract considering sequential urine cultures (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).<elsevierMultimedia ident="tbl0010"></elsevierMultimedia>Epidemiology and risk factors for UTI in SOT recipientsSome risk factors have been described for the development of UTI in SOT recipients (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).<elsevierMultimedia ident="tbl0015"></elsevierMultimedia>RecommendationsShould SOT recipients receive primary prophylaxis for UTI?<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0060">1.Trimethoprim/sulfamethoxazole (TMP/SMX, cotrimoxazole 160–800mg) antibiotic prophylaxis is recommended during the first 3–6 months post-transplant because it significantly decreases AB and symptomatic UTI, and bacteremia in renal transplant recipients (A-I).</li><li class="elsevierStyleListItem" id="lsti0065">2.Antibiotic prophylaxis is not specifically recommended for UTI in non-kidney SOT recipients.What should be the management of asymptomatic bacteriuria in SOT recipients?</li><li class="elsevierStyleListItem" id="lsti0070">3.Screening for and treatment of AB in kidney transplant recipients (KTR) is recommended in the early postoperative period and up to one month after transplantation (B-III).</li><li class="elsevierStyleListItem" id="lsti0075">4.There is not enough evidence to recommend continued screening for and treatment of AB in a clinically stable KTR beyond one month after transplantation (C-III). However, there is no consensus on whether AB by multidrug resistant (MDR) bacteria, mainly Gram-negative bacilli, should be treated.</li><li class="elsevierStyleListItem" id="lsti0080">5.Screening for and treatment of AB is not currently recommended for other SOT recipients (D-III). In these cases, guidelines for the general population should be applied.</li><li class="elsevierStyleListItem" id="lsti0085">6.Treatment of asymptomatic candiduria is not currently recommended for SOT recipients. Among patients with a urinary catheter, removal of the catheter may be sufficient to eliminate candiduria without specific antifungal therapy (D-III).</li><li class="elsevierStyleListItem" id="lsti0090">7.Urine culture screening of patients awaiting transplantation is not routinely recommended (D-III).</li><li class="elsevierStyleListItem" id="lsti0095">8.Live donors should be screened and treated for bacteriuria before the organ is harvested (A-III).What is the best empirical treatment of UTI in SOT recipients? (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>)<elsevierMultimedia ident="tbl0020"></elsevierMultimedia></li><li class="elsevierStyleListItem" id="lsti0100">9.The treatment strategy depends on the time elapsed since transplantation and the severity of the illness (B-III).</li><li class="elsevierStyleListItem" id="lsti0105">10.The choice of empirical antimicrobial agents should be based on local epidemiological data and the patient's history of previous resistant organisms (A-II).</li><li class="elsevierStyleListItem" id="lsti0110">11.Antibiotic therapies prescribed in the previous months should be taken into account (B-III).</li><li class="elsevierStyleListItem" id="lsti0115">12.Review if the patient has recurrent episodes of UTI. The incidence of resistant organisms can rise progressively with the number of episodes (C-III).</li><li class="elsevierStyleListItem" id="lsti0120">13.Especially if resistant organisms are found, expanded antimicrobial testing should be requested from the microbiology lab to identify treatment options for completion of therapy (B-III).</li><li class="elsevierStyleListItem" id="lsti0125">14.Consider removal or replacement of urinary tract instruments such as urethral catheters or urologic stents (B-III).</li><li class="elsevierStyleListItem" id="lsti0130">15.Progression of upper urinary tract disease to a renal or perinephric abscess or emphysematous pyelonephritis usually requires a multidisciplinary approach to treatment, including urologist and/or interventional radiology consultation for percutaneous or surgical drainage of abscesses (A-I).</li><li class="elsevierStyleListItem" id="lsti0135">16.Once culture susceptibility results are available, switch to the narrowest spectrum antibiotic available to complete course of therapy (B-III).</li><li class="elsevierStyleListItem" id="lsti0140">17.Adjust the antibiotic dosage according to the patient's renal function (A-I).</li><li class="elsevierStyleListItem" id="lsti0145">18.In the event of severe infection with sepsis, consider the option of reducing/discontinuing the immunosuppression therapy (B-III).What is the best definitive treatment of UTI in SOT recipients?</li><li class="elsevierStyleListItem" id="lsti0150">19.To choose an appropriate antibiotic for the treatment of cystitis caused by Enterobacteriaceae, the recommendations for the general population are adapted to organ transplant patients. For hospitalized patients, we recommend using cotrimoxazole or second- or third-generation oral cephalosporin or amoxicillin–clavulanate or fosfomycin trometamol for susceptible strains (B-I). For outpatients, we recommend ciprofloxacin or fosfomycin trometamol (B-I). For the treatment of cystitis caused by extended-spectrum beta-lactamase (ESBL)-producing E. coli, we recommend fosfomycin trometamol (B-I). For cystitis caused by carbapenem-resistant Enterobacteriaceae, we recommend using either fosfomycin trometamol or aminoglycosides (gentamicin or amikacin) (B-II). Contrary to most recommendations for the general population, nitrofurantoin is not recommended as a first-line treatment of cystitis due to the potential occurrence of adverse effects in patients with SOT (D-III).</li><li class="elsevierStyleListItem" id="lsti0155">20.For the treatment of hospitalized patients with acute pyelonephritis caused by Enterobacteriaceae, we recommend the use of a beta-lactam, either third-generation cephalosporins or amoxicillin–clavulanate (B-I). After discharge or in outpatients, we recommend the use of fluoroquinolones (B-I). For pyelonephritis caused by ESBL-producing Enterobacteriaceae, we recommend ertapenem (B-I). Monotherapy with a carbapenem is not recommended for patients with invasive infections caused by carbapenemase-producing Enterobacteriaceae but may be considered in cases of mild invasive infections if adequate source control is readily achieved and the isolate is susceptible (C-III). For patients in which combination therapy is indicated, a regimen with a carbapenem plus one or two fully active drugs (including colistin, an aminoglycoside, or fosfomycin) is recommended if the carbapenem minimum inhibitory concentration (MIC) is ≤8mg/L; this applies mainly to patients with severe infections caused by KPC-producing Klebsiella pneumoniae (B-II). There are not enough data to recommend including a carbapenem in combination regimens if MIC is >8mg/L. If this is the case, carbapenems are probably useless. Particularly if MIC is >16mg/L, we recommend including at least two fully active drugs in the combination regimen according to susceptibility testing results (drugs to be considered: colistin, aminoglycosides, and fosfomycin) (C-III).</li><li class="elsevierStyleListItem" id="lsti0160">21.For the treatment of cystitis caused by Pseudomonas aeruginosa, we recommend ciprofloxacin for susceptible strains (B-III). For pyelonephritis by P. aeruginosa we recommend the use, when possible, of beta-lactams active against P. aeruginosa in hospitalized patients and quinolones in outpatients (B-III). For the treatment of pyelonephritis by multidrug-resistant P. aeruginosa, we recommend colistin or amikacin with monitoring of renal function when no other options are available (C-III).</li><li class="elsevierStyleListItem" id="lsti0165">22.For ampicillin-susceptible enterococci strains, we recommend oral amoxicillin for the treatment of cystitis (B-III) and intravenous ampicillin for the treatment of pyelonephritis (C-III). For ampicillin-resistant Enterococcus faecium, we recommend glycopeptides (C-III). For vancomycin-resistant Enterococcus strains, the treatment should be guided by antibiogram and we recommend the use of quinolones, cotrimoxazole, fosfomycin, nitrofurantoin, and linezolid in order of preference (B-III).</li><li class="elsevierStyleListItem" id="lsti0170">23.For the treatment of infected cysts in patients with renal polycystic disease, we recommend the use of fluoroquinolones or TMP/SMX when possible and percutaneous drainage if necessary (B-III).</li><li class="elsevierStyleListItem" id="lsti0175">24.For the treatment of acute prostatitis we recommend intravenous beta-lactams until apyrexia and consolidation treatment with fluoroquinolones or TMP/SMX when possible (B-I).How long should SOT recipients receive antibiotics for a UTI?</li><li class="elsevierStyleListItem" id="lsti0180">25.Kidney recipients presenting AB within the first month of transplantation should receive an oral antibiotic selected according to the susceptibility of the isolated microorganism for a period of 5–7 days (BIII). In other SOT recipients, guidelines for the general population should be applied (AII).</li><li class="elsevierStyleListItem" id="lsti0185">26.Cystitis in SOT recipients should be treated for 5–7 days with an oral antibiotic. Early post-transplant cystitis in renal transplant recipients may require longer treatment, especially if a ureteral stent is present (BIII). Short courses of therapy (single dose or three days) have not been studied in SOT recipients (CIII).</li><li class="elsevierStyleListItem" id="lsti0190">27.KTR with allograft pyelonephritis should undergo a 14-day course of antibiotics. However, patients with allograft pyelonephritis in the early post-transplant period presenting with sepsis should be treated for at least 14–21 days (BIII). Late uncomplicated allograft pyelonephritis occurring more than six months after kidney transplantation may be treated with antibiotic therapy for 10–14 days (BIII). At least initially, intravenous antibiotic therapy is recommended in kidney recipients with allograft pyelonephritis (AIII).</li><li class="elsevierStyleListItem" id="lsti0195">28.In non-kidney SOT recipients with uncomplicated pyelonephritis, a 10- to 14-day course of antibiotics is recommended (BIII). At least initially, these patients should be treated with intravenous antibiotics (AIII).</li><li class="elsevierStyleListItem" id="lsti0200">29.No data are available on short courses (7 days) of antibiotic therapy for pyelonephritis in SOT recipients. Therefore, short-term treatment is not recommended in SOT (CIII).</li><li class="elsevierStyleListItem" id="lsti0205">30.For SOT recipients with complicated pyelonephritis, an antibiotic course of at least two weeks is recommended and should be extended until abscesses are adequately drained and patient improvement has been achieved (BIII).</li><li class="elsevierStyleListItem" id="lsti0210">31.For SOT recipients with acute bacterial prostatitis, a 2- to 4-week course of antibiotics is recommended. However, antibiotic therapy can be continued for up to four weeks in patients with severe illness, concomitant bacteremia, and undrained abscesses (BIII).</li><li class="elsevierStyleListItem" id="lsti0215">32.In SOT recipients with polycystic kidney disease and infected cysts, treatment of not less than 14 days is recommended and may be extended depending on patient evolution, cyst diameter, and possibility of drainage (BIII).What should be the management of UTI caused by Candida spp. in SOT recipients?What should be the initial diagnostic approach to a SOT recipient with candiduria?</li><li class="elsevierStyleListItem" id="lsti0220">33.SOT recipients with candiduria should be classified according to the presence of risk factors for disseminated candidiasis, indications for obtaining a urine culture (surveillance or infection suspicion), and according to their clinical situation (asymptomatic, with urinary tract symptoms or with general manifestations of sepsis) (A-III).</li><li class="elsevierStyleListItem" id="lsti0225">34.Predisposing risk factors should be eliminated or controlled (antibiotic use, malnutrition, hyperglycemia) and urinary catheters should be removed or at least changed if possible. The presence of candiduria should be verified with a second, clean-voided urine culture (A-II).</li><li class="elsevierStyleListItem" id="lsti0230">35.Disseminated candidiasis should be considered in all hospitalized SOT with candiduria. If clinical manifestations are compatible, blood cultures, a second urine culture after removal or replacement of the urinary catheter, fundoscopy, cultures from any other significant site (vascular accesses, peritoneal fluid, etc.), and a kidney imaging study should be obtained (AII).</li><li class="elsevierStyleListItem" id="lsti0235">36.Patients with persistent candiduria and no indwelling bladder catheter should undergo imaging of the kidneys and collecting system to exclude renal abscess, fungus balls, or other urologic abnormalities (A-II).</li><li class="elsevierStyleListItem" id="lsti0240">37.SOT recipients in whom Candida contamination of the preservation fluid is demonstrated or suspected (donors with ruptured abdominal viscus at the time of multiorgan recovery) should undergo urgent diagnostic evaluation including Doppler ultrasound, blood and urine cultures, and cultures from any other significant site (B-III).Which patients should receive antifungal drugs?</li><li class="elsevierStyleListItem" id="lsti0245">38.Asymptomatic candiduria in SOT patients that are not neutropenic or undergoing a urologic procedure should not be treated with antifungal therapy (D-II).</li><li class="elsevierStyleListItem" id="lsti0250">39.Candiduria in an unstable SOT should be initially considered as a potential marker of disseminated candidiasis. Prompt effective antifungal therapy has to be provided until an alternative diagnosis is obtained (A-III).</li><li class="elsevierStyleListItem" id="lsti0255">40.Candida cystitis or pyelonephritis should be treated with systemic antifungals for 2–4 weeks (B-III).</li><li class="elsevierStyleListItem" id="lsti0260">41.Fungus balls or casts in the pelvis or urinary bladder need surgery and systemic and/or local antifungal therapy (A-III).</li><li class="elsevierStyleListItem" id="lsti0265">42.KTR with contamination of the preservation fluid or with a donor with digestive tract rupture should receive early effective antifungal therapy (B-II).Which drug should be prescribed and for how long? (<a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>)<elsevierMultimedia ident="tbl0025"></elsevierMultimedia></li><li class="elsevierStyleListItem" id="lsti0270">43.Fluconazole is the agent of choice for most patients with Candida UTI due to the high concentration achieved in urine (>100μg/ml, which is 10-fold the simultaneous plasma level) (A-II).</li><li class="elsevierStyleListItem" id="lsti0275">44.Other antifungal agents should only be considered for patients in unstable clinical condition, allergic to fluconazole, or in whom therapy has clearly failed despite maximum fluconazole doses and optimal management of urologic abnormalities or other predisposing conditions (B-III).</li><li class="elsevierStyleListItem" id="lsti0280">45.A single dose of parenteral amphotericin B (AMB) deoxycholate, with or without oral 5-flucytosine, reach high concentrations in urine, and may be used to treat Candida cystitis in patients not responding to or not treatable with fluconazole. Candida pyelonephritis can also be treated with AMB. However, potential kidney toxicity limits its use in the transplant population (B-I).</li><li class="elsevierStyleListItem" id="lsti0285">46.Liposomal AMB, with or without 5-flucytosine, may be used to treat Candida pyelonephritis in patients not responding to or not treatable with fluconazole. However, due to the low concentration reached in urine, a relapse may occur if the collecting system is infected (C-III).</li><li class="elsevierStyleListItem" id="lsti0290">47.AMB deoxycholate bladder irrigation may be used in patients with symptomatic cystitis that cannot be treated with other drugs (C-II).</li><li class="elsevierStyleListItem" id="lsti0295">48.Echinocandins are the preferred initial agents for systemic candidiasis in unstable patients, in patients who have been exposed to azoles in the previous 3 months, and in patients with renal insufficiency requiring external replacement therapy (A-I).</li><li class="elsevierStyleListItem" id="lsti0300">49.Echinocandins achieve low concentrations in the urinary tract but may be used in patients not responding to or not treatable with fluconazole. If the collecting system is infected, relapse may occur (C-III).</li><li class="elsevierStyleListItem" id="lsti0305">50.All symptomatic UTIs due to Candida species in KTR should be considered complicated and treated for at least 14 days (B-II).What should be the diagnostic–therapeutic management of recurrent UTI in SOT recipients?</li><li class="elsevierStyleListItem" id="lsti0310">51.The diagnostic approach in transplant patients with recurrent UTI must be meticulous in order to rule out the existence of anatomical or functional changes (A-III).</li><li class="elsevierStyleListItem" id="lsti0315">52.If possible, treatment aimed at the sensitivity of the isolated microorganisms must be used in patients with recurrent UTI. TMP/SMX is a good option (B-III). Quinolones must be avoided as empirical therapy (D-II).</li><li class="elsevierStyleListItem" id="lsti0320">53.Duration of antibiotic treatment for recurrent UTIs in transplant patients is not well-defined. At least a 6-week treatment period may be recommendable (B-III), although other authors suggest prolonging treatment more than three months. Indefinite treatment may be evaluated in diabetic patients, patients with a history of UTIs before or soon after transplantation and those receiving high-dose immunosuppressive treatment (equivalent to secondary prophylaxis) (B-II).</li><li class="elsevierStyleListItem" id="lsti0325">54.Anatomical changes related with recurrent UTI must be corrected if possible (A-II).</li><li class="elsevierStyleListItem" id="lsti0330">55.The use of non-antibiotic therapies, such as cranberry extract, l-methionine, topical estrogens, or topical application of Lactobacillus, could be provided to transplant patients with recurrent UTI (C-II).What role does UTI play in kidney graft rejection or dysfunction?</li><li class="elsevierStyleListItem" id="lsti0335">56.Kidney transplant patients are particularly vulnerable to infections, and this is one of the reasons for which primary prophylaxis has been established (A-I) and early aggressive treatment of symptomatic UTI is recommended (A-II).</li><li class="elsevierStyleListItem" id="lsti0340">57.Although UTI has been associated with induction of acute rejection in kidney transplant patients (A-II), there is controversy about the final impact on the graft in terms of chronic rejection or dysfunction (B-II).</li><li class="elsevierStyleListItem" id="lsti0345">58.Late-onset UTIs, which were traditionally associated with a good prognosis, have also been recently related with a risk of rejection or dysfunction of the kidney graft (B-II).</li><li class="elsevierStyleListItem" id="lsti0350">59.The association between AB and graft loss is unclear.Antimicrobial and immunosuppressant interactions (<a class="elsevierStyleCrossRefs" href="#tbl0030">Tables 6–11</a>)<elsevierMultimedia ident="tbl0030"></elsevierMultimedia><elsevierMultimedia ident="tbl0035"></elsevierMultimedia><elsevierMultimedia ident="tbl0040"></elsevierMultimedia><elsevierMultimedia ident="tbl0045"></elsevierMultimedia><elsevierMultimedia ident="tbl0050"></elsevierMultimedia><elsevierMultimedia ident="tbl0055"></elsevierMultimedia></li><li class="elsevierStyleListItem" id="lsti0355">60.The treatment of UTIs in SOT recipients is more complex due to interactions between antimicrobials and immunosuppressants.</li><li class="elsevierStyleListItem" id="lsti0360">61.The interactions may jeopardize the transplanted organ and also increase the specific adverse effects of each drug.</li><li class="elsevierStyleListItem" id="lsti0365">62.Key measures to avoid the consequences of these interactions are to know and to prevent them by monitoring the plasma levels of these drugs, monitoring graft function and characteristic adverse effects, and avoiding contraindicated combinations (AII).</li></ul>Conflict of interestJMC has received a conference grant from Astellas, Astra-Zeneca, MSD, Novartis, and Pfizer. All other authors have no conflict of interest to declare." "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres587771" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec603522" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres587772" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec603521" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Methods" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Definitions" "secciones" => array:8 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Bacteriuria" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Cystitis" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Pyelonephritis" ] 3 => array:2 [ "identificador" => "sec0035" "titulo" => "Reinfection" ] 4 => array:2 [ "identificador" => "sec0040" "titulo" => "Relapse" ] 5 => array:2 [ "identificador" => "sec0045" "titulo" => "Recurrent infection" ] 6 => array:2 [ "identificador" => "sec0050" "titulo" => "Complicated urinary tract infection" ] 7 => array:2 [ "identificador" => "sec0055" "titulo" => "Prostatitis" ] ] ] 7 => array:2 [ "identificador" => "sec0060" "titulo" => "Epidemiology and risk factors for UTI in SOT recipients" ] 8 => array:2 [ "identificador" => "sec0065" "titulo" => "Recommendations" ] 9 => array:2 [ "identificador" => "sec0070" "titulo" => "Conflict of interest" ] 10 => array:2 [ "identificador" => "xack197727" "titulo" => "Acknowledgements" ] 11 => array:1 [ "titulo" => "Reference" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec603522" "palabras" => array:5 [ 0 => "Urinary infection" 1 => "Transplantation" 2 => "Consensus" 3 => "Prophylaxis" 4 => "Treatment" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec603521" "palabras" => array:5 [ 0 => "Infección urinaria" 1 => "Trasplante" 2 => "Consenso" 3 => "Profilaxis" 4 => "Tratamiento" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Urinary tract infections (UTI) are one of the most common infections in solid organ transplant (SOT) recipients. A systematic review was performed to assess the management of UTI in SOT recipients.Recommendations are provided on the management of asymptomatic bacteriuria, and prophylaxis and treatment of UTI in SOT recipients. The diagnostic–therapeutic management of recurrent UTI and the role of infection in kidney graft rejection or dysfunction are reviewed. Finally, recommendations on antimicrobials and immunosuppressant interactions are also included." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "Las infecciones del tracto urinario (ITU) son muy frecuentes en los receptores de un trasplante de órgano sólido (TOS). Hemos realizado una revisión sistemática para determinar el abordaje de la ITU en receptores de TOS.Se realizan recomendaciones sobre el abordaje de la bacteriuria asintomática y sobre la profilaxis y tratamiento de las ITU en receptores de TOS. Se han revisado el abordaje diagnóstico-terapéutico de las ITU recurrentes y el papel de la ITU en el rechazo o disfunción del injerto renal. Finalmente, se incluyen recomendaciones sobre las interacciones entre antimicrobianos e inmunosupresores." ] ] "NotaPie" => array:1 [ 0 => array:3 [ "etiqueta" => "◊" "nota" => "Coordinators of the document. These authors contributed equally to this work." "identificador" => "fn1" ] ] "multimedia" => array:11 [ 0 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Category, grade \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Definition \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Strength of recommendation</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Solid evidence of efficacy and clinical benefit \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Solid or moderately solid evidence of efficacy, but clinical benefit is limited \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Insufficient evidence of efficacy or possible benefits in terms of efficacy do not outweigh the cost or risks (toxicity and drug interactions), valid alternatives are available \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">D \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Moderately solid evidence of a lack of efficacy or poor outcome \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">E \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Strong evidence of a lack of efficacy or poor outcome \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Quality of evidence</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">I \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Evidence from at least 1 well-designed and performed trial \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Evidence from at least 1 well-designed non-randomized clinical trial, cohort study, or a non-controlled experimental study with non-conclusive results \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Expert opinion based on clinical experience, descriptive studies, or reports from expert panels \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959789.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Classification of the recommendations of this consensus document based on the strength and quality of the evidence analyzed." ] ] 1 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "Stamey T. Pathogenesis and Treatment of Urinary Tract Infections. Baltimore: Williams & Wilkins; 1980." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sample \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Symbol \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Description \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Bladder emptying 1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">BE1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Initial 5–10ml of urine stream \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Bladder emptying 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">BE2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Sample midstream urinary \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Expressed prostatic secretions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">EPS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Secretions obtained from transrectal prostate by digital massage \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Bladder emptying 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">BE3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">First 5–10ml of urine stream immediately after prostatic massage \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959782.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Definitive diagnosis of bacterial prostatitis requires that the number of colonies in the BE3 sample exceeds those in the BE1 sample, preferably by more than 10 times. However, the prostate of many patients with chronic prostatitis contains only small amounts of bacteria. In these patients, a prostatic secretions culture is particularly useful. Microscopic examination of the EPS is useful to identify leukocytes and “oval fat bodies” – large lipid-laden macrophages characteristic of prostatic inflammatory response." ] ] ] "descripcion" => array:1 [ "en" => "Sequential urine cultures for anatomical location within the lower urinary tract.<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a>" ] ] 2 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Female gender \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Age \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Mycophenolate mofetil \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Antithymocyte globulin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Need for immediate post-transplant dialysis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Ureteral stent placement >30 days \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Diabetes mellitus \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Deceased-donor kidneys \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Number of episodes of acute rejection \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Reflux kidney disease prior to transplantation \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Length of hospitalization \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Length of urinary catheterization \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Number of episodes of acute rejection \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Post-transplant urinary obstructions \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Increase in immunosuppression \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959787.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Risk factors for urinary tract infections in solid organ transplantation." ] ] 3 => array:7 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "In all cases, once culture susceptibility results are available, complete therapy with the most narrow-spectrum antibiotic available." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Clinical presentation \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Absence of risk factors for multidrug-resistant (MDR) organisms \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Presence of risk factors for MDR organisms<a class="elsevierStyleCrossRef" href="#tblfn0020">c</a> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Cystitis<a class="elsevierStyleCrossRef" href="#tblfn0010">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fosfomycin or amoxicillin/clavulanate or second/third generation oral cephalosporins \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fosfomycin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">If recurrence is suspected, consider potential infection for MDR organisms \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Alternative therapies: ertapenem, pivmecillinam if available \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Alternative therapy: TMP/SMX or ciprofloxacin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Acute uncomplicated pyelonephritis<a class="elsevierStyleCrossRef" href="#tblfn0015">b</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Ceftriaxone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Ertapenem or piperacillin-tazobactam \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Alternative therapy: amoxicillin/clavulanate or aztreonam (if beta-lactam allergy) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Alternative therapies: aztreonam+vancomycin (if beta-lactam allergy) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Severe sepsis/septic shock \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Meropenem±vancomycin (if risk factors for enterococcal infection)±amikacin (if risk factors for P. aeruginosa) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Meropenem+vancomycin/linezolid (if risk factors for enterococcal infection)±amikacin (if risk factors for P. aeruginosa)If potential infection by extensively-drug resistant (XDR) P. aeruginosa or carbapenem-resistant Enterobacteriaceae or MDR A. baumannii, consider expert consultation \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Alternative therapies: aztreonam+vancomycin±amikacin (if risk factors for P. aeruginosa) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Alternative therapies: aztreonam/colistin+vancomycin/linezolid (if risk factors for enterococcal infection)±amikacin (if risk factors for P. aeruginosa) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959785.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "a" "nota" => "Dysuria, urgency, frequency, suprapubic pain without fever, and presence of a urine bacteria count >105cfu/ml." ] 1 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "b" "nota" => "Fever, chills, flank/allograft pain, and presence of a urine bacteria count >105cfu/ml." ] 2 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "c" "nota" => "Prior hospitalization (within 3 months), previous antibiotic therapy (within 1 month), previous colonization by MDR organisms, reoperation, nosocomial infection, post-transplant hemodialysis, and nephrostomy." ] ] ] "descripcion" => array:1 [ "en" => "Empirical treatment of urinary tract infections in solid organ transplant recipients." ] ] 4 => array:7 [ "identificador" => "tbl0025" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Agent \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Indications \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Dose \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Comments \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Fluconazole \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Drug of choice for Candida cystitis and pyelonephritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Loading dose 12mg/kg, followed by 6mg/kg/d IV or PO (≥400mg/d for symptomatic candiduria) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Hepatotoxicity in patients with liver insufficiency \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Antifungal prophylaxis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Not recommended in patients with renal replacement therapy \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Preemptive therapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Adjust dose if renal failure and systemic candidiasis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Targeted therapy for systemic candidiasis caused by susceptible strains in stable patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Drug interactions: warfarin, coumadin, oral contraceptives, benzodiazepines, cyclosporine, rifampicin, tacrolimus and others. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">d-AMB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Very rarely needed \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Parenteral 0.3–1mg/kg/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Renal insufficiency \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Symptomatic cystitis or pyelonephritis in patients not responding to or not treatable with fluconazole \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Continuous or intermittent bladder irrigation: 50mg in 1L (50μg/ml) 1-7d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Bladder irritation. Cumbersome \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Drug interactions: cisplatin, pentamidine, aminoglycosides, cyclosporine, corticoids and others. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Candins \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Initial drugs of choice for systemic candidiasis in unstable patients, in patients who have been exposed to azoles in the previous 3 months and in patients with renal insufficiency requiring external replacement therapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Anidulafungin 200mg/d loading dose, followed by 100mg/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Preferred if recent azole exposure, patients in septic shock or with external renal devices \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Candida pyelonephritis in patients not responding to or not treatable with fluconazole \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Micafungin 100mg/d IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Low urine concentration. Relapse may occur if the collecting system is the source of the candidemia \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Caspofungin 70mg loading dose, followed by 50mg/d IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Drug interactions: Anidulafungin (none), Micafungin (sirolimus, nifedipine, itraconazole), Caspofungin (cyclosporine, tacrolimus, efavirenz, nevirapine, rifampicin, dexamethasone, phenytoin, carbamazepine) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">L-AMB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Candida pyelonephritis in patients not responding to or not treatable with fluconazole \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3mg/kg/d IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Low urine and kidney concentration. Relapse may occur \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Drug interactions: digoxin, aminoglycosides, cyclosporine and others. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Voriconazole \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Candida pyelonephritis in patients not responding to or not treatable with fluconazole \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6mg/kg/d two loading doses, followed by 3mg/kg/12h IV or PO \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Low urine concentration. Relapse may occur \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Drug interactions: rifabutin, rifampicin, methadone, ritonavir, efavirenz, carbamazepine, ranitidine, macrolides, sirolimus, cyclosporine, tacrolimus, warfarin, coumadin, statins, benzodiazepines, omeprazole, oral contraceptives and others. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Monitor serum levels. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">5-flucytosine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Symptomatic cystitis in patients not responding to or not treatable with fluconazole \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25mg/kg every 6h 7–10 d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Emergence of resistance if given alone or for prolonged periods. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Adjust dose if renal insufficiency. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Gastrointestinal, liver and bone marrow toxicity \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959786.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Antifungal drugs." ] ] 5 => array:7 [ "identificador" => "tbl0030" "etiqueta" => "Table 6" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "AMK: amikacin; GEN: gentamicin; ETM: streptomycin; EPT: spectinomycin; KAN: kanamycin; TOB: tobramycin." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">AMK \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">GEN \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ETM \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">EPT \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">KAN \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TOB \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Cyclosporine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Tacrolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Mycophenolate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Sirolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Everolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Azathioprine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Prednisone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Basiliximab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Muromonab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959788.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0025" "etiqueta" => "a" "nota" => "A/a: these drugs should not be co-administered; B/b: potential interaction – may require monitoring of plasma levels and graft function and/or change in dose; C/c: no clinically relevant interactions; A, B, C: indicate that interaction has been described; a, b, c: indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product." ] ] ] "descripcion" => array:1 [ "en" => "Interactions between aminoglycosides and immunosuppressants.<a class="elsevierStyleCrossRef" href="#tblfn0025">a</a>" ] ] 6 => array:7 [ "identificador" => "tbl0035" "etiqueta" => "Table 7" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "AMP: ampicillin; AMC: amoxicillin–clavulanate; CLO: cloxacillin; NAF: nafcillin; CFU: cefuroxime; CFZ: ceftazidime; CFX: ceftriaxone; AZT: aztreonam; IMI: imipenem; TIC: ticarcillin." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">AMP \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">AMC \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CLO \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">NAF \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CFU \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CFZ \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CFX \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">AZT \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IMI \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TIC \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Cyclosporine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Tacrolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Mycophenolate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Sirolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Everolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Azathioprine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Prednisone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Basiliximab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Muromonab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959781.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0030" "etiqueta" => "a" "nota" => "A/a: these drugs should not be co-administered; B/b: potential interaction – may require monitoring of plasma levels and graft function and/or change in dose; C/c: no clinically relevant interactions; A, B, C: indicate that interaction has been described; a, b, c: indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product." ] ] ] "descripcion" => array:1 [ "en" => "Interactions between beta-lactams and immunosuppressants.<a class="elsevierStyleCrossRef" href="#tblfn0030">a</a>" ] ] 7 => array:7 [ "identificador" => "tbl0040" "etiqueta" => "Table 8" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "CIP: ciprofloxacin; LEV: levofloxacin; MOX: moxifloxacin; NAL: nalidixic acid; NOR: norfloxacin; OFL: ofloxacin." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CIP \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">LEV \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MOX \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">NAL \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">NOR \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">OFL \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Cyclosporine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Tacrolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Mycophenolate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Sirolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Everolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Azathioprine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Prednisone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Basiliximab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Muromonab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959784.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0035" "etiqueta" => "a" "nota" => "A/a: these drugs should not be co-administered; B/b: potential interaction – may require monitoring of plasma levels and graft function and/or change in dose; C/c: no clinically relevant interactions; NA: data not available; A, B, C: indicate that interaction has been described; a, b, c: indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product." ] ] ] "descripcion" => array:1 [ "en" => "Interactions between quinolones and immunosuppressants.<a class="elsevierStyleCrossRef" href="#tblfn0035">a</a>" ] ] 8 => array:7 [ "identificador" => "tbl0045" "etiqueta" => "Table 9" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "TIG: tigecycline; VAN: vancomycin; DAP: daptomycin; LIN: linezolid; COT: cotrimoxazole; DOX: doxycycline; FOS: fosfomycin; CLI: clindamycin; MET: metronidazole; FID: fidaxomicin.NA: Not analyzed." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TIG \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">VAN \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">DAP \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">LIN \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">COT \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">DOX \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">FOS \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CLI \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MET \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">FID \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Cyclosporine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Tacrolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Mycophenolate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Sirolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Everolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Azathioprine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Prednisone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Basiliximab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Muromonab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959783.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0040" "etiqueta" => "a" "nota" => "A/a: these drugs should not be co-administered; B/b: potential interaction – may require monitoring of plasma levels and graft function and/or change in dose; C/c: no clinically relevant interactions; NA: data not available; A, B, C: indicate that interaction has been described; a, b, c: indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product." ] ] ] "descripcion" => array:1 [ "en" => "Interactions between other antibiotics and immunosuppressants.<a class="elsevierStyleCrossRef" href="#tblfn0040">a</a>" ] ] 9 => array:7 [ "identificador" => "tbl0050" "etiqueta" => "Table 10" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "KET: ketoconazole; ITR: itraconazole; FLU: fluconazole; VOR: voriconazole; POS: posaconazole; CAS: caspofungin; MIC: micafungin; ANI: anidulafungin." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">KET \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ITR \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">FLU \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">VOR \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">POS \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CAS \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MIC \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ANI \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Cyclosporine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0050">b</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0050">b</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0055">c</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Tacrolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0060">d</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0060">d</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0060">d</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Mycophenolate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Sirolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0065">e</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Everolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Azathioprine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Prednisone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Basiliximab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Muromonab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959790.png" ] ] ] "notaPie" => array:5 [ 0 => array:3 [ "identificador" => "tblfn0045" "etiqueta" => "a" "nota" => "A/a: these drugs should not be co-administered; B/b: potential interaction – may require monitoring of plasma levels and graft function and/or change in dose; C/c: no clinically relevant interactions; NA: data not available; A, B, C: indicate that interaction has been described; a, b, c: indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product." ] 1 => array:3 [ "identificador" => "tblfn0050" "etiqueta" => "b" "nota" => "It is recommended to reduce the dose of cyclosporine=50%." ] 2 => array:3 [ "identificador" => "tblfn0055" "etiqueta" => "c" "nota" => "It is recommended to reduce the dose of cyclosporine=25%." ] 3 => array:3 [ "identificador" => "tblfn0060" "etiqueta" => "d" "nota" => "It is recommended to reduce the dose of tacrolimus=33%." ] 4 => array:3 [ "identificador" => "tblfn0065" "etiqueta" => "e" "nota" => "It is recommended to reduce the dose of sirolimus=50%." ] ] ] "descripcion" => array:1 [ "en" => "Interactions between azoles, echinocandins and immunosuppressants.<a class="elsevierStyleCrossRef" href="#tblfn0045">a</a>" ] ] 10 => array:7 [ "identificador" => "tbl0055" "etiqueta" => "Table 11" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "FUC: flucytosine; ABD: amphotericin B deoxycholate; ABL: liposomal amphotericin B; ABC: amphotericin lipid complex." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">FUC \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ABD \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ABL \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ABC \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Cyclosporine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Tacrolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Mycophenolate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Sirolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Everolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Azathioprine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Prednisone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Basiliximab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Muromonab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab959780.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0070" "etiqueta" => "a" "nota" => "A/a: these drugs should not be co-administered; B/b: potential interaction – may require monitoring of plasma levels and graft function and/or change in dose; C/c: no clinically relevant interactions; NA: data not available; A, B, C: indicate that interaction has been described; a, b, c: indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product." ] ] ] "descripcion" => array:1 [ "en" => "Interactions between flucytosine, polyenes and immunosuppressants.<a class="elsevierStyleCrossRef" href="#tblfn0070">a</a>" ] ] ] "bibliografia" => array:2 [ "titulo" => "Reference" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:1 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in infectious Diseases (REIPI)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Vidal" 1 => "C. Cervera" 2 => "E. Cordero" 3 => "C. Armiñanzas" 4 => "J. Carratalá" 5 => "J.M. Cisneros" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Enferm Infecc Microbiol Clin" "fecha" => "2015" "volumen" => "33" "paginaInicial" => "679.e1" "paginaFinal" => "679.e21" ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack197727" "titulo" => "Acknowledgements" "texto" => "We thank Jesús Rodríguez-Baño MD, PhD and member of SEIMC for his comments on the manuscript." "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/0213005X/0000003300000010/v1_201512110028/S0213005X15001433/v1_201512110028/en/main.assets" "Apartado" => array:4 [ "identificador" => "44301" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Documentos de consenso" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/0213005X/0000003300000010/v1_201512110028/S0213005X15001433/v1_201512110028/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X15001433?idApp=UINPBA00004N"]

Statistics

Consensus statement

Executive summary. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI)

Executive summary. Abordaje de la infección urinaria en receptores de trasplante de órgano sólido: documento de consenso del Grupo de Estudio de la Infección en Receptores de Trasplante (GESITRA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y la Red Española para el Estudio de Patología Infecciosa (REIPI)

Elisa Vidala,◊,

Corresponding author

vidal.elisa@gmail.com

Corresponding author.

, Carlos Cerverab,◊, Elisa Corderoc, Carlos Armiñanzasd, Jordi Carrataláe, José Miguel Cisnerosc, M. Carmen Fariñasd, Francisco López-Medranof, Asunción Morenob, Patricia Muñozg, Julia Origüenf, Núria Sabée, Maricela Valeriog, Julián Torre-Cisnerosa, Study Group of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases, Clinical Microbiology (SEIMC), Spanish Network for Research in Infectious Diseases (REIPI)

a Unidad Clínica de Gestión de Enfermedades Infecciosas, Instituto Maimónides de Investigación en Biomedicina de Córdoba, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain

b Servicio de Enfermedades Infecciosas, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, Spain

c Unidad Clínica de Gestión de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain

d Unidad de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain

e Servicio de Enfermedades Infecciosas, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Universidad de Barcelona, Barcelona, Spain

f Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Instituto de Investigación Biomédica 12 de Octubre, Departamento de Medicina, Universidad Complutense, Madrid, Spain

g Departamento de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Read

6327

Times
was read the article

1850

Total PDF

4477

Total HTML

Share statistics

 array:23 [
  "pii" => "S0213005X15001433"
  "issn" => "0213005X"
  "doi" => "10.1016/j.eimc.2015.03.020"
  "estado" => "S300"
  "fechaPublicacion" => "2015-12-01"
  "aid" => "1328"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; y Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica"
  "copyrightAnyo" => "2015"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "pgl"
  "cita" => "Enferm Infecc Microbiol Clin. 2015;33:680-7"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 2695
    "formatos" => array:3 [
      "EPUB" => 12
      "HTML" => 1721
      "PDF" => 962
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0213005X15000774"
    "issn" => "0213005X"
    "doi" => "10.1016/j.eimc.2015.02.008"
    "estado" => "S300"
    "fechaPublicacion" => "2015-12-01"
    "aid" => "1295"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; y Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Enferm Infecc Microbiol Clin. 2015;33:688-9"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 3713
      "formatos" => array:3 [
        "EPUB" => 18
        "HTML" => 2919
        "PDF" => 776
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Diagn&#243;stico a primera vista</span>"
      "titulo" => "N&#243;dulos fluctuantes en el cuero cabelludo de un ni&#241;o"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "688"
          "paginaFinal" => "689"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Fluctuating nodules on the scalp of a child"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1046
              "Ancho" => 1500
              "Tamanyo" => 354983
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A&#44; B y C&#46; Cuero cabelludo con m&#250;ltiples n&#243;dulos eritematosos&#44; fluctuantes&#44; con &#225;reas alop&#233;cicas en su superficie&#44; acompa&#241;ados de abundantes p&#250;stulas&#46; D&#46; Cultivo de hongos&#44; en el que se observan colonias de color blanco-amarillento&#46; E&#46; Preparaci&#243;n te&#241;ida con azul de lactofenol&#44; en la que se observan hifas septadas con macroconidias de extremos aguzados&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Juan Manr&#237;quez, Sergio Niklitschek"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Juan"
              "apellidos" => "Manr&#237;quez"
            ]
            1 => array:2 [
              "nombre" => "Sergio"
              "apellidos" => "Niklitschek"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X15000774?idApp=UINPBA00004N"
    "url" => "/0213005X/0000003300000010/v1_201512110028/S0213005X15000774/v1_201512110028/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0213005X15001470"
    "issn" => "0213005X"
    "doi" => "10.1016/j.eimc.2015.03.024"
    "estado" => "S300"
    "fechaPublicacion" => "2015-12-01"
    "aid" => "1332"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; y Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "pgl"
    "cita" => "Enferm Infecc Microbiol Clin. 2015;33:679&#46;e1-679&#46;e21"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 9425
      "formatos" => array:3 [
        "EPUB" => 16
        "HTML" => 8064
        "PDF" => 1345
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Consensus statement</span>"
      "titulo" => "Management of urinary tract infection in solid organ transplant recipients&#58; Consensus statement of the Group for the Study of Infection in Transplant Recipients &#40;GESITRA&#41; of the Spanish Society of Infectious Diseases and Clinical Microbiology &#40;SEIMC&#41; and the Spanish Network for Research in Infectious Diseases &#40;REIPI&#41;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "679&#46;e1"
          "paginaFinal" => "679&#46;e21"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Tratamiento de la infecci&#243;n del tracto urinario en los receptores de trasplantes de &#243;rganos s&#243;lidos&#58; Declaraci&#243;n de consenso del Grupo de Estudio de Infecci&#243;n en receptores de trasplantes &#40;GESITRA&#41; de la Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica &#40;SEIMC&#41; y la Red Espa&#241;ola de Investigaci&#243;n en Patolog&#237;a Infecciosa &#40;REIPI&#41;"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Elisa Vidal, Carlos Cervera, Elisa Cordero, Carlos Armi&#241;anzas, Jordi Carratal&#225;, Jos&#233; Miguel Cisneros, M&#46; Carmen Fari&#241;as, Francisco L&#243;pez-Medrano, Asunci&#243;n Moreno, Patricia Mu&#241;oz, Julia Orig&#252;en, N&#250;ria Sab&#233;, Maricela Valerio, Juli&#225;n Torre-Cisneros"
          "autores" => array:16 [
            0 => array:2 [
              "nombre" => "Elisa"
              "apellidos" => "Vidal"
            ]
            1 => array:2 [
              "nombre" => "Carlos"
              "apellidos" => "Cervera"
            ]
            2 => array:2 [
              "nombre" => "Elisa"
              "apellidos" => "Cordero"
            ]
            3 => array:2 [
              "nombre" => "Carlos"
              "apellidos" => "Armi&#241;anzas"
            ]
            4 => array:2 [
              "nombre" => "Jordi"
              "apellidos" => "Carratal&#225;"
            ]
            5 => array:2 [
              "nombre" => "Jos&#233; Miguel"
              "apellidos" => "Cisneros"
            ]
            6 => array:2 [
              "nombre" => "M&#46; Carmen"
              "apellidos" => "Fari&#241;as"
            ]
            7 => array:2 [
              "nombre" => "Francisco"
              "apellidos" => "L&#243;pez-Medrano"
            ]
            8 => array:2 [
              "nombre" => "Asunci&#243;n"
              "apellidos" => "Moreno"
            ]
            9 => array:2 [
              "nombre" => "Patricia"
              "apellidos" => "Mu&#241;oz"
            ]
            10 => array:2 [
              "nombre" => "Julia"
              "apellidos" => "Orig&#252;en"
            ]
            11 => array:2 [
              "nombre" => "N&#250;ria"
              "apellidos" => "Sab&#233;"
            ]
            12 => array:2 [
              "nombre" => "Maricela"
              "apellidos" => "Valerio"
            ]
            13 => array:2 [
              "nombre" => "Juli&#225;n"
              "apellidos" => "Torre-Cisneros"
            ]
            14 => array:1 [
              "colaborador" => "Study Group of Infection in Transplant Recipients &#40;GESITRA&#41; of the Spanish Society of Infectious Diseases&#44; Clinical Microbiology &#40;SEIMC&#41;"
            ]
            15 => array:1 [
              "colaborador" => "Spanish Network for Research in Infectious Diseases &#40;REIPI&#41;"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X15001470?idApp=UINPBA00004N"
    "url" => "/0213005X/0000003300000010/v1_201512110028/S0213005X15001470/v1_201512110028/en/main.assets"
  ]
  "en" => array:18 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Consensus statement</span>"
    "titulo" => "Executive summary&#46; Management of urinary tract infection in solid organ transplant recipients&#58; Consensus statement of the Group for the Study of Infection in Transplant Recipients &#40;GESITRA&#41; of the Spanish Society of Infectious Diseases and Clinical Microbiology &#40;SEIMC&#41; and the Spanish Network for Research in Infectious Diseases &#40;REIPI&#41;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "680"
        "paginaFinal" => "687"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Elisa Vidal, Carlos Cervera, Elisa Cordero, Carlos Armi&#241;anzas, Jordi Carratal&#225;, Jos&#233; Miguel Cisneros, M&#46; Carmen Fari&#241;as, Francisco L&#243;pez-Medrano, Asunci&#243;n Moreno, Patricia Mu&#241;oz, Julia Orig&#252;en, N&#250;ria Sab&#233;, Maricela Valerio, Juli&#225;n Torre-Cisneros"
        "autores" => array:15 [
          0 => array:4 [
            "nombre" => "Elisa"
            "apellidos" => "Vidal"
            "email" => array:1 [
              0 => "vidal&#46;elisa&#64;gmail&#46;com"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#9674;</span>"
                "identificador" => "fn1"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Carlos"
            "apellidos" => "Cervera"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#9674;</span>"
                "identificador" => "fn1"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Elisa"
            "apellidos" => "Cordero"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Carlos"
            "apellidos" => "Armi&#241;anzas"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Jordi"
            "apellidos" => "Carratal&#225;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Jos&#233; Miguel"
            "apellidos" => "Cisneros"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "M&#46; Carmen"
            "apellidos" => "Fari&#241;as"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Francisco"
            "apellidos" => "L&#243;pez-Medrano"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Asunci&#243;n"
            "apellidos" => "Moreno"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Patricia"
            "apellidos" => "Mu&#241;oz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "Julia"
            "apellidos" => "Orig&#252;en"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "N&#250;ria"
            "apellidos" => "Sab&#233;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          12 => array:3 [
            "nombre" => "Maricela"
            "apellidos" => "Valerio"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          13 => array:3 [
            "nombre" => "Juli&#225;n"
            "apellidos" => "Torre-Cisneros"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          14 => array:1 [
            "colaborador" => "Study Group of Infection in Transplant Recipients &#40;GESITRA&#41; of the Spanish Society of Infectious Diseases&#44; Clinical Microbiology &#40;SEIMC&#41;&#44; Spanish Network for Research in Infectious Diseases &#40;REIPI&#41;"
          ]
        ]
        "afiliaciones" => array:7 [
          0 => array:3 [
            "entidad" => "Unidad Cl&#237;nica de Gesti&#243;n de Enfermedades Infecciosas&#44; Instituto Maim&#243;nides de Investigaci&#243;n en Biomedicina de C&#243;rdoba&#44; Hospital Universitario Reina Sof&#237;a&#44; Universidad de C&#243;rdoba&#44; C&#243;rdoba&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Enfermedades Infecciosas&#44; Hospital Cl&#237;nic-Institut d&#8217;Investigacions Biom&#232;diques August Pi i Sunyer &#40;IDIBAPS&#41;&#44; Universidad de Barcelona&#44; Barcelona&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Unidad Cl&#237;nica de Gesti&#243;n de Enfermedades Infecciosas&#44; Microbiolog&#237;a y Medicina Preventiva&#44; Instituto de Biomedicina de Sevilla&#44; Hospital Universitario Virgen del Roc&#237;o&#44; Universidad de Sevilla&#44; Sevilla&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Unidad de Enfermedades Infecciosas&#44; Hospital Universitario Marqu&#233;s de Valdecilla&#44; Universidad de Cantabria&#44; IDIVAL&#44; Santander&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Enfermedades Infecciosas&#44; Hospital Universitario de Bellvitge&#44; Instituto de Investigaci&#243;n Biom&#233;dica de Bellvitge &#40;IDIBELL&#41;&#44; Universidad de Barcelona&#44; Barcelona&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Unidad de Enfermedades Infecciosas&#44; Hospital Universitario 12 de Octubre&#44; Instituto de Investigaci&#243;n Biom&#233;dica 12 de Octubre&#44; Departamento de Medicina&#44; Universidad Complutense&#44; Madrid&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Departamento de Microbiolog&#237;a Cl&#237;nica y Enfermedades Infecciosas&#44; Hospital General Universitario Gregorio Mara&#241;&#243;n&#44; Madrid&#44; Spain"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Executive summary&#46; Abordaje de la infecci&#243;n urinaria en receptores de trasplante de &#243;rgano s&#243;lido&#58; documento de consenso del Grupo de Estudio de la Infecci&#243;n en Receptores de Trasplante &#40;GESITRA&#41; de la Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica &#40;SEIMC&#41; y la Red Espa&#241;ola para el Estudio de Patolog&#237;a Infecciosa &#40;REIPI&#41;"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The use of solid organ transplantation &#40;SOT&#41; has been established as accepted therapy for end-stage disease of the kidneys&#44; liver&#44; heart&#44; and lungs for nearly 30 years&#46; Intestinal and pancreas transplantation are also generally available but are provided on a more limited basis&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Infections remain a major cause of morbidity and mortality in transplant recipients&#46; Urinary tract infections &#40;UTI&#41; are one of the most common infections in SOT&#44; with a high prevalence&#44; reaching 75&#37; in some series involving kidney recipients&#46; Experienced SOT researchers and clinicians have developed and implemented this consensus document in support of the optimal management of these patients&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">The target population of this document are adults receiving SOT&#46; The intended guideline audience is physicians involved in the care of SOT recipients &#40;including primary care physicians&#41;&#46; Here we report a consensus with the objective of assessing the overall available evidence and to propose recommendations on the following key issues&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1&#46;</span><p id="par0020" class="elsevierStylePara elsevierViewall">Definitions&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2&#46;</span><p id="par0025" class="elsevierStylePara elsevierViewall">Epidemiology and risk factors for UTI in SOT recipients&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3&#46;</span><p id="par0030" class="elsevierStylePara elsevierViewall">Should SOT recipients receive primary prophylaxis for UTI&#63;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4&#46;</span><p id="par0035" class="elsevierStylePara elsevierViewall">What should be the management of asymptomatic bacteriuria in SOT recipients&#63;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">5&#46;</span><p id="par0040" class="elsevierStylePara elsevierViewall">What is the best empirical treatment of UTI in SOT recipients&#63;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">6&#46;</span><p id="par0045" class="elsevierStylePara elsevierViewall">What is the best definitive treatment of UTI in SOT recipients&#63;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">7&#46;</span><p id="par0050" class="elsevierStylePara elsevierViewall">How long should SOT recipients receive antibiotics for a UTI&#63;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">8&#46;</span><p id="par0055" class="elsevierStylePara elsevierViewall">What should be the management of UTI caused by <span class="elsevierStyleItalic">Candida</span> spp&#46; in SOT recipients&#63;</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">9&#46;</span><p id="par0060" class="elsevierStylePara elsevierViewall">What should be the diagnostic&#8211;therapeutic management of recurrent UTI in SOT recipients&#63;</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">10&#46;</span><p id="par0065" class="elsevierStylePara elsevierViewall">What role does UTI play in kidney graft rejection or dysfunction&#63;</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">11&#46;</span><p id="par0070" class="elsevierStylePara elsevierViewall">Antimicrobial and immunosuppressant interactions&#46;</p></li></ul></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Methods</span><p id="par0075" class="elsevierStylePara elsevierViewall">We conducted a systematic review to assess the management of UTI in SOT recipients&#46; Data for this document were identified through a search of PubMed and references from relevant articles using the search terms &#8220;transplant&#8221; and &#8220;urinary tract infection&#8221;&#46; The search criteria included articles in English that involved human participants&#46; We selected and revised a total of 3043 articles from 1968 to June 2014&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">The evidence level based on the available literature is given for each recommendation to assess the strength of the evidence for risk and benefits of the procedure&#46; This article was written in accordance with international recommendations on consensus statements &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41; and the recommendations of the Appraisal of Guidelines for Research and Evaluation II &#40;AGREE II&#41;&#46; The authors met twice to discuss the consensus and establish formal recommendations&#46; The coordinators and authors agree on the content and conclusions&#46; The consensus statement was sent to the 96 members of GESITRA for external revision of the manuscript&#46; The board of directors of GESITRA will designate the coordinators to update the statements within 5 years&#46; The full version of the consensus document of this executive summary is available at Ref&#46; <a class="elsevierStyleCrossRef" href="#bib0005">1</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Definitions</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Bacteriuria</span><p id="par0085" class="elsevierStylePara elsevierViewall">Bacteriuria is defined according to the criteria proposed by the Infectious Diseases Society of America guidelines&#46; For asymptomatic women&#44; bacteriuria is defined as 2 consecutive voided urine specimens with isolation of the same bacterial strain in quantitative counts &#8805;10<span class="elsevierStyleSup">5</span> colony-forming units &#40;cfu&#41;&#47;ml&#46; A single&#44; clean-catch voided urine specimen with 1 bacterial species isolated in a quantitative count &#8805;10<span class="elsevierStyleSup">5</span><span class="elsevierStyleHsp" style=""></span>cfu&#47;ml identifies bacteriuria in men&#46; A single catheterized urine specimen with 1 bacterial species isolated in a quantitative count &#8805;10<span class="elsevierStyleSup">2</span><span class="elsevierStyleHsp" style=""></span>cfu&#47;ml identifies bacteriuria in women or men&#46; Asymptomatic bacteriuria &#40;AB&#41; is defined by the presence of bacteriuria in the absence of any symptoms of lower or upper UTI&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Cystitis</span><p id="par0090" class="elsevierStylePara elsevierViewall">Cystitis is defined by the presence of bacteriuria and clinical manifestations such as dysuria&#44; frequency&#44; or urinary urgency in the absence of pyelonephritis criteria&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Pyelonephritis</span><p id="par0095" class="elsevierStylePara elsevierViewall">Pyelonephritis is defined by the simultaneous presence of a urine bacteria count &#8805;10<span class="elsevierStyleSup">5</span><span class="elsevierStyleHsp" style=""></span>cfu&#47;ml and&#47;or bacteremia and fever with one or more of the following four categories&#58; costovertebral angle pain &#40;if native kidney involved&#41;&#44; renal allograft tenderness &#40;if transplanted kidney involved&#41;&#44; chills&#44; criteria for cystitis &#40;bacteriuria and clinical manifestations such as dysuria&#44; frequency&#44; or urinary urgency&#41;&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Reinfection</span><p id="par0100" class="elsevierStylePara elsevierViewall">Reinfection is defined by a new episode of infection with the isolation of bacterium other than the one that caused the previous infection or the same bacteria with a different antibiotic sensitivity pattern&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Relapse</span><p id="par0105" class="elsevierStylePara elsevierViewall">Relapse is defined as the isolation of the same microorganism that caused the preceding infection&#44; with the same antibiotic sensitivity pattern&#44; in a urine culture obtained &#8805;2 weeks after finishing the previous treatment&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Recurrent infection</span><p id="par0110" class="elsevierStylePara elsevierViewall">Recurrent infection is commonly defined as three or more episodes of symptomatic UTIs over a 12-month period or two episodes in the previous six months&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Complicated urinary tract infection</span><p id="par0115" class="elsevierStylePara elsevierViewall">A complicated UTI is defined as an infection that is associated with structural or functional abnormalities of the genitourinary tract&#44; or the presence of an underlying disease that increases the risk of acquiring an infection or of failing therapy&#46;</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Prostatitis</span><p id="par0120" class="elsevierStylePara elsevierViewall">Prostatitis is characterized by discomfort referred to the lower urogenital and perineal and&#47;or ejaculatory discomfort or sexual dysfunction&#46; Acute bacterial prostatitis is presented as fever and chills accompanied by urinary symptoms such as dysuria&#44; frequency&#44; and perineal pain&#46; Chronic bacterial prostatitis has a more prolonged course&#44; usually of at least 3 months&#46; This is usually related to or the result of recurrent urinary infection&#44; or may be a complication of acute prostatitis that is not properly cured&#44; urethritis&#44; or epididymitis&#46; The disease can occur continuously or episodically&#46; The symptoms are milder than in acute prostatitis and sometimes imperceptible&#46; The most common symptoms are perineal or pelvic pain&#44; low back pain&#44; testicular pain&#44; and discomfort when urinating or ejaculating&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">The classification of patients with prostatitis depends on the bacteriological study of lower urinary tract considering sequential urine cultures &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Epidemiology and risk factors for UTI in SOT recipients</span><p id="par0130" class="elsevierStylePara elsevierViewall">Some risk factors have been described for the development of UTI in SOT recipients &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Recommendations</span><p id="par0140" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Should SOT recipients receive primary prophylaxis for UTI&#63;</span><ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">1&#46;</span><p id="par0145" class="elsevierStylePara elsevierViewall">Trimethoprim&#47;sulfamethoxazole &#40;TMP&#47;SMX&#44; cotrimoxazole 160&#8211;800<span class="elsevierStyleHsp" style=""></span>mg&#41; antibiotic prophylaxis is recommended during the first 3&#8211;6 months post-transplant because it significantly decreases AB and symptomatic UTI&#44; and bacteremia in renal transplant recipients &#40;A-I&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0065"><span class="elsevierStyleLabel">2&#46;</span><p id="par0150" class="elsevierStylePara elsevierViewall">Antibiotic prophylaxis is not specifically recommended for UTI in non-kidney SOT recipients&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">What should be the management of asymptomatic bacteriuria in SOT recipients&#63;</span></p></li><li class="elsevierStyleListItem" id="lsti0070"><span class="elsevierStyleLabel">3&#46;</span><p id="par0160" class="elsevierStylePara elsevierViewall">Screening for and treatment of AB in kidney transplant recipients &#40;KTR&#41; is recommended in the early postoperative period and up to one month after transplantation &#40;B-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0075"><span class="elsevierStyleLabel">4&#46;</span><p id="par0165" class="elsevierStylePara elsevierViewall">There is not enough evidence to recommend continued screening for and treatment of AB in a clinically stable KTR beyond one month after transplantation &#40;C-III&#41;&#46; However&#44; there is no consensus on whether AB by multidrug resistant &#40;MDR&#41; bacteria&#44; mainly Gram-negative bacilli&#44; should be treated&#46;</p></li><li class="elsevierStyleListItem" id="lsti0080"><span class="elsevierStyleLabel">5&#46;</span><p id="par0170" class="elsevierStylePara elsevierViewall">Screening for and treatment of AB is not currently recommended for other SOT recipients &#40;D-III&#41;&#46; In these cases&#44; guidelines for the general population should be applied&#46;</p></li><li class="elsevierStyleListItem" id="lsti0085"><span class="elsevierStyleLabel">6&#46;</span><p id="par0175" class="elsevierStylePara elsevierViewall">Treatment of asymptomatic candiduria is not currently recommended for SOT recipients&#46; Among patients with a urinary catheter&#44; removal of the catheter may be sufficient to eliminate candiduria without specific antifungal therapy &#40;D-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0090"><span class="elsevierStyleLabel">7&#46;</span><p id="par0180" class="elsevierStylePara elsevierViewall">Urine culture screening of patients awaiting transplantation is not routinely recommended &#40;D-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0095"><span class="elsevierStyleLabel">8&#46;</span><p id="par0185" class="elsevierStylePara elsevierViewall">Live donors should be screened and treated for bacteriuria before the organ is harvested &#40;A-III&#41;&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">What is the best empirical treatment of UTI in SOT recipients&#63;</span> &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>&#41;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></li><li class="elsevierStyleListItem" id="lsti0100"><span class="elsevierStyleLabel">9&#46;</span><p id="par0195" class="elsevierStylePara elsevierViewall">The treatment strategy depends on the time elapsed since transplantation and the severity of the illness &#40;B-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0105"><span class="elsevierStyleLabel">10&#46;</span><p id="par0200" class="elsevierStylePara elsevierViewall">The choice of empirical antimicrobial agents should be based on local epidemiological data and the patient&#39;s history of previous resistant organisms &#40;A-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0110"><span class="elsevierStyleLabel">11&#46;</span><p id="par0205" class="elsevierStylePara elsevierViewall">Antibiotic therapies prescribed in the previous months should be taken into account &#40;B-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0115"><span class="elsevierStyleLabel">12&#46;</span><p id="par0210" class="elsevierStylePara elsevierViewall">Review if the patient has recurrent episodes of UTI&#46; The incidence of resistant organisms can rise progressively with the number of episodes &#40;C-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0120"><span class="elsevierStyleLabel">13&#46;</span><p id="par0215" class="elsevierStylePara elsevierViewall">Especially if resistant organisms are found&#44; expanded antimicrobial testing should be requested from the microbiology lab to identify treatment options for completion of therapy &#40;B-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0125"><span class="elsevierStyleLabel">14&#46;</span><p id="par0220" class="elsevierStylePara elsevierViewall">Consider removal or replacement of urinary tract instruments such as urethral catheters or urologic stents &#40;B-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0130"><span class="elsevierStyleLabel">15&#46;</span><p id="par0225" class="elsevierStylePara elsevierViewall">Progression of upper urinary tract disease to a renal or perinephric abscess or emphysematous pyelonephritis usually requires a multidisciplinary approach to treatment&#44; including urologist and&#47;or interventional radiology consultation for percutaneous or surgical drainage of abscesses &#40;A-I&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0135"><span class="elsevierStyleLabel">16&#46;</span><p id="par0230" class="elsevierStylePara elsevierViewall">Once culture susceptibility results are available&#44; switch to the narrowest spectrum antibiotic available to complete course of therapy &#40;B-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0140"><span class="elsevierStyleLabel">17&#46;</span><p id="par0235" class="elsevierStylePara elsevierViewall">Adjust the antibiotic dosage according to the patient&#39;s renal function &#40;A-I&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0145"><span class="elsevierStyleLabel">18&#46;</span><p id="par0240" class="elsevierStylePara elsevierViewall">In the event of severe infection with sepsis&#44; consider the option of reducing&#47;discontinuing the immunosuppression therapy &#40;B-III&#41;&#46;</p><p id="par0245" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">What is the best definitive treatment of UTI in SOT recipients&#63;</span></p></li><li class="elsevierStyleListItem" id="lsti0150"><span class="elsevierStyleLabel">19&#46;</span><p id="par0250" class="elsevierStylePara elsevierViewall">To choose an appropriate antibiotic for the treatment of cystitis caused by <span class="elsevierStyleItalic">Enterobacteriaceae</span>&#44; the recommendations for the general population are adapted to organ transplant patients&#46; For hospitalized patients&#44; we recommend using cotrimoxazole or second- or third-generation oral cephalosporin or amoxicillin&#8211;clavulanate or fosfomycin trometamol for susceptible strains &#40;B-I&#41;&#46; For outpatients&#44; we recommend ciprofloxacin or fosfomycin trometamol &#40;B-I&#41;&#46; For the treatment of cystitis caused by extended-spectrum beta-lactamase &#40;ESBL&#41;-producing <span class="elsevierStyleItalic">E&#46; coli</span>&#44; we recommend fosfomycin trometamol &#40;B-I&#41;&#46; For cystitis caused by carbapenem-resistant <span class="elsevierStyleItalic">Enterobacteriaceae</span>&#44; we recommend using either fosfomycin trometamol or aminoglycosides &#40;gentamicin or amikacin&#41; &#40;B-II&#41;&#46; Contrary to most recommendations for the general population&#44; nitrofurantoin is not recommended as a first-line treatment of cystitis due to the potential occurrence of adverse effects in patients with SOT &#40;D-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0155"><span class="elsevierStyleLabel">20&#46;</span><p id="par0255" class="elsevierStylePara elsevierViewall">For the treatment of hospitalized patients with acute pyelonephritis caused by <span class="elsevierStyleItalic">Enterobacteriaceae</span>&#44; we recommend the use of a beta-lactam&#44; either third-generation cephalosporins or amoxicillin&#8211;clavulanate &#40;B-I&#41;&#46; After discharge or in outpatients&#44; we recommend the use of fluoroquinolones &#40;B-I&#41;&#46; For pyelonephritis caused by ESBL-producing <span class="elsevierStyleItalic">Enterobacteriaceae</span>&#44; we recommend ertapenem &#40;B-I&#41;&#46; Monotherapy with a carbapenem is not recommended for patients with invasive infections caused by carbapenemase-producing <span class="elsevierStyleItalic">Enterobacteriaceae</span> but may be considered in cases of mild invasive infections if adequate source control is readily achieved and the isolate is susceptible &#40;C-III&#41;&#46; For patients in which combination therapy is indicated&#44; a regimen with a carbapenem plus one or two fully active drugs &#40;including colistin&#44; an aminoglycoside&#44; or fosfomycin&#41; is recommended if the carbapenem minimum inhibitory concentration &#40;MIC&#41; is &#8804;8<span class="elsevierStyleHsp" style=""></span>mg&#47;L&#59; this applies mainly to patients with severe infections caused by KPC-producing <span class="elsevierStyleItalic">Klebsiella pneumoniae</span> &#40;B-II&#41;&#46; There are not enough data to recommend including a carbapenem in combination regimens if MIC is &#62;8<span class="elsevierStyleHsp" style=""></span>mg&#47;L&#46; If this is the case&#44; carbapenems are probably useless&#46; Particularly if MIC is &#62;16<span class="elsevierStyleHsp" style=""></span>mg&#47;L&#44; we recommend including at least two fully active drugs in the combination regimen according to susceptibility testing results &#40;drugs to be considered&#58; colistin&#44; aminoglycosides&#44; and fosfomycin&#41; &#40;C-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0160"><span class="elsevierStyleLabel">21&#46;</span><p id="par0260" class="elsevierStylePara elsevierViewall">For the treatment of cystitis caused by <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span>&#44; we recommend ciprofloxacin for susceptible strains &#40;B-III&#41;&#46; For pyelonephritis by <span class="elsevierStyleItalic">P&#46; aeruginosa</span> we recommend the use&#44; when possible&#44; of beta-lactams active against <span class="elsevierStyleItalic">P&#46; aeruginosa</span> in hospitalized patients and quinolones in outpatients &#40;B-III&#41;&#46; For the treatment of pyelonephritis by multidrug-resistant <span class="elsevierStyleItalic">P&#46; aeruginosa</span>&#44; we recommend colistin or amikacin with monitoring of renal function when no other options are available &#40;C-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0165"><span class="elsevierStyleLabel">22&#46;</span><p id="par0265" class="elsevierStylePara elsevierViewall">For ampicillin-susceptible enterococci strains&#44; we recommend oral amoxicillin for the treatment of cystitis &#40;B-III&#41; and intravenous ampicillin for the treatment of pyelonephritis &#40;C-III&#41;&#46; For ampicillin-resistant <span class="elsevierStyleItalic">Enterococcus faecium</span>&#44; we recommend glycopeptides &#40;C-III&#41;&#46; For vancomycin-resistant <span class="elsevierStyleItalic">Enterococcus</span> strains&#44; the treatment should be guided by antibiogram and we recommend the use of quinolones&#44; cotrimoxazole&#44; fosfomycin&#44; nitrofurantoin&#44; and linezolid in order of preference &#40;B-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0170"><span class="elsevierStyleLabel">23&#46;</span><p id="par0270" class="elsevierStylePara elsevierViewall">For the treatment of infected cysts in patients with renal polycystic disease&#44; we recommend the use of fluoroquinolones or TMP&#47;SMX when possible and percutaneous drainage if necessary &#40;B-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0175"><span class="elsevierStyleLabel">24&#46;</span><p id="par0275" class="elsevierStylePara elsevierViewall">For the treatment of acute prostatitis we recommend intravenous beta-lactams until apyrexia and consolidation treatment with fluoroquinolones or TMP&#47;SMX when possible &#40;B-I&#41;&#46;</p><p id="par0280" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">How long should SOT recipients receive antibiotics for a UTI&#63;</span></p></li><li class="elsevierStyleListItem" id="lsti0180"><span class="elsevierStyleLabel">25&#46;</span><p id="par0285" class="elsevierStylePara elsevierViewall">Kidney recipients presenting AB within the first month of transplantation should receive an oral antibiotic selected according to the susceptibility of the isolated microorganism for a period of 5&#8211;7 days &#40;BIII&#41;&#46; In other SOT recipients&#44; guidelines for the general population should be applied &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0185"><span class="elsevierStyleLabel">26&#46;</span><p id="par0290" class="elsevierStylePara elsevierViewall">Cystitis in SOT recipients should be treated for 5&#8211;7 days with an oral antibiotic&#46; Early post-transplant cystitis in renal transplant recipients may require longer treatment&#44; especially if a ureteral stent is present &#40;BIII&#41;&#46; Short courses of therapy &#40;single dose or three days&#41; have not been studied in SOT recipients &#40;CIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0190"><span class="elsevierStyleLabel">27&#46;</span><p id="par0295" class="elsevierStylePara elsevierViewall">KTR with allograft pyelonephritis should undergo a 14-day course of antibiotics&#46; However&#44; patients with allograft pyelonephritis in the early post-transplant period presenting with sepsis should be treated for at least 14&#8211;21 days &#40;BIII&#41;&#46; Late uncomplicated allograft pyelonephritis occurring more than six months after kidney transplantation may be treated with antibiotic therapy for 10&#8211;14 days &#40;BIII&#41;&#46; At least initially&#44; intravenous antibiotic therapy is recommended in kidney recipients with allograft pyelonephritis &#40;AIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0195"><span class="elsevierStyleLabel">28&#46;</span><p id="par0300" class="elsevierStylePara elsevierViewall">In non-kidney SOT recipients with uncomplicated pyelonephritis&#44; a 10- to 14-day course of antibiotics is recommended &#40;BIII&#41;&#46; At least initially&#44; these patients should be treated with intravenous antibiotics &#40;AIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0200"><span class="elsevierStyleLabel">29&#46;</span><p id="par0305" class="elsevierStylePara elsevierViewall">No data are available on short courses &#40;7 days&#41; of antibiotic therapy for pyelonephritis in SOT recipients&#46; Therefore&#44; short-term treatment is not recommended in SOT &#40;CIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0205"><span class="elsevierStyleLabel">30&#46;</span><p id="par0310" class="elsevierStylePara elsevierViewall">For SOT recipients with complicated pyelonephritis&#44; an antibiotic course of at least two weeks is recommended and should be extended until abscesses are adequately drained and patient improvement has been achieved &#40;BIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0210"><span class="elsevierStyleLabel">31&#46;</span><p id="par0315" class="elsevierStylePara elsevierViewall">For SOT recipients with acute bacterial prostatitis&#44; a 2- to 4-week course of antibiotics is recommended&#46; However&#44; antibiotic therapy can be continued for up to four weeks in patients with severe illness&#44; concomitant bacteremia&#44; and undrained abscesses &#40;BIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0215"><span class="elsevierStyleLabel">32&#46;</span><p id="par0320" class="elsevierStylePara elsevierViewall">In SOT recipients with polycystic kidney disease and infected cysts&#44; treatment of not less than 14 days is recommended and may be extended depending on patient evolution&#44; cyst diameter&#44; and possibility of drainage &#40;BIII&#41;&#46;</p><p id="par0325" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">What should be the management of UTI caused by Candida spp&#46; in SOT recipients&#63;</span></p><p id="par0330" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">What should be the initial diagnostic approach to a SOT recipient with candiduria&#63;</span></p></li><li class="elsevierStyleListItem" id="lsti0220"><span class="elsevierStyleLabel">33&#46;</span><p id="par0335" class="elsevierStylePara elsevierViewall">SOT recipients with candiduria should be classified according to the presence of risk factors for disseminated candidiasis&#44; indications for obtaining a urine culture &#40;surveillance or infection suspicion&#41;&#44; and according to their clinical situation &#40;asymptomatic&#44; with urinary tract symptoms or with general manifestations of sepsis&#41; &#40;A-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0225"><span class="elsevierStyleLabel">34&#46;</span><p id="par0340" class="elsevierStylePara elsevierViewall">Predisposing risk factors should be eliminated or controlled &#40;antibiotic use&#44; malnutrition&#44; hyperglycemia&#41; and urinary catheters should be removed or at least changed if possible&#46; The presence of candiduria should be verified with a second&#44; clean-voided urine culture &#40;A-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0230"><span class="elsevierStyleLabel">35&#46;</span><p id="par0345" class="elsevierStylePara elsevierViewall">Disseminated candidiasis should be considered in all hospitalized SOT with candiduria&#46; If clinical manifestations are compatible&#44; blood cultures&#44; a second urine culture after removal or replacement of the urinary catheter&#44; fundoscopy&#44; cultures from any other significant site &#40;vascular accesses&#44; peritoneal fluid&#44; etc&#46;&#41;&#44; and a kidney imaging study should be obtained &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0235"><span class="elsevierStyleLabel">36&#46;</span><p id="par0350" class="elsevierStylePara elsevierViewall">Patients with persistent candiduria and no indwelling bladder catheter should undergo imaging of the kidneys and collecting system to exclude renal abscess&#44; fungus balls&#44; or other urologic abnormalities &#40;A-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0240"><span class="elsevierStyleLabel">37&#46;</span><p id="par0355" class="elsevierStylePara elsevierViewall">SOT recipients in whom <span class="elsevierStyleItalic">Candida</span> contamination of the preservation fluid is demonstrated or suspected &#40;donors with ruptured abdominal viscus at the time of multiorgan recovery&#41; should undergo urgent diagnostic evaluation including Doppler ultrasound&#44; blood and urine cultures&#44; and cultures from any other significant site &#40;B-III&#41;&#46;</p><p id="par0360" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Which patients should receive antifungal drugs&#63;</span></p></li><li class="elsevierStyleListItem" id="lsti0245"><span class="elsevierStyleLabel">38&#46;</span><p id="par0365" class="elsevierStylePara elsevierViewall">Asymptomatic candiduria in SOT patients that are not neutropenic or undergoing a urologic procedure should not be treated with antifungal therapy &#40;D-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0250"><span class="elsevierStyleLabel">39&#46;</span><p id="par0370" class="elsevierStylePara elsevierViewall">Candiduria in an unstable SOT should be initially considered as a potential marker of disseminated candidiasis&#46; Prompt effective antifungal therapy has to be provided until an alternative diagnosis is obtained &#40;A-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0255"><span class="elsevierStyleLabel">40&#46;</span><p id="par0375" class="elsevierStylePara elsevierViewall">Candida cystitis or pyelonephritis should be treated with systemic antifungals for 2&#8211;4 weeks &#40;B-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0260"><span class="elsevierStyleLabel">41&#46;</span><p id="par0380" class="elsevierStylePara elsevierViewall">Fungus balls or casts in the pelvis or urinary bladder need surgery and systemic and&#47;or local antifungal therapy &#40;A-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0265"><span class="elsevierStyleLabel">42&#46;</span><p id="par0385" class="elsevierStylePara elsevierViewall">KTR with contamination of the preservation fluid or with a donor with digestive tract rupture should receive early effective antifungal therapy &#40;B-II&#41;&#46;</p><p id="par0390" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Which drug should be prescribed and for how long&#63;</span> &#40;<a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>&#41;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia></li><li class="elsevierStyleListItem" id="lsti0270"><span class="elsevierStyleLabel">43&#46;</span><p id="par0395" class="elsevierStylePara elsevierViewall">Fluconazole is the agent of choice for most patients with <span class="elsevierStyleItalic">Candida</span> UTI due to the high concentration achieved in urine &#40;&#62;100<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;ml&#44; which is 10-fold the simultaneous plasma level&#41; &#40;A-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0275"><span class="elsevierStyleLabel">44&#46;</span><p id="par0400" class="elsevierStylePara elsevierViewall">Other antifungal agents should only be considered for patients in unstable clinical condition&#44; allergic to fluconazole&#44; or in whom therapy has clearly failed despite maximum fluconazole doses and optimal management of urologic abnormalities or other predisposing conditions &#40;B-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0280"><span class="elsevierStyleLabel">45&#46;</span><p id="par0405" class="elsevierStylePara elsevierViewall">A single dose of parenteral amphotericin B &#40;AMB&#41; deoxycholate&#44; with or without oral 5-flucytosine&#44; reach high concentrations in urine&#44; and may be used to treat <span class="elsevierStyleItalic">Candida</span> cystitis in patients not responding to or not treatable with fluconazole&#46; <span class="elsevierStyleItalic">Candida</span> pyelonephritis can also be treated with AMB&#46; However&#44; potential kidney toxicity limits its use in the transplant population &#40;B-I&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0285"><span class="elsevierStyleLabel">46&#46;</span><p id="par0410" class="elsevierStylePara elsevierViewall">Liposomal AMB&#44; with or without 5-flucytosine&#44; may be used to treat <span class="elsevierStyleItalic">Candida</span> pyelonephritis in patients not responding to or not treatable with fluconazole&#46; However&#44; due to the low concentration reached in urine&#44; a relapse may occur if the collecting system is infected &#40;C-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0290"><span class="elsevierStyleLabel">47&#46;</span><p id="par0415" class="elsevierStylePara elsevierViewall">AMB deoxycholate bladder irrigation may be used in patients with symptomatic cystitis that cannot be treated with other drugs &#40;C-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0295"><span class="elsevierStyleLabel">48&#46;</span><p id="par0420" class="elsevierStylePara elsevierViewall">Echinocandins are the preferred initial agents for systemic candidiasis in unstable patients&#44; in patients who have been exposed to azoles in the previous 3 months&#44; and in patients with renal insufficiency requiring external replacement therapy &#40;A-I&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0300"><span class="elsevierStyleLabel">49&#46;</span><p id="par0425" class="elsevierStylePara elsevierViewall">Echinocandins achieve low concentrations in the urinary tract but may be used in patients not responding to or not treatable with fluconazole&#46; If the collecting system is infected&#44; relapse may occur &#40;C-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0305"><span class="elsevierStyleLabel">50&#46;</span><p id="par0430" class="elsevierStylePara elsevierViewall">All symptomatic UTIs due to <span class="elsevierStyleItalic">Candida</span> species in KTR should be considered complicated and treated for at least 14 days &#40;B-II&#41;&#46;</p><p id="par0435" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">What should be the diagnostic&#8211;therapeutic management of recurrent UTI in SOT recipients&#63;</span></p></li><li class="elsevierStyleListItem" id="lsti0310"><span class="elsevierStyleLabel">51&#46;</span><p id="par0440" class="elsevierStylePara elsevierViewall">The diagnostic approach in transplant patients with recurrent UTI must be meticulous in order to rule out the existence of anatomical or functional changes &#40;A-III&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0315"><span class="elsevierStyleLabel">52&#46;</span><p id="par0445" class="elsevierStylePara elsevierViewall">If possible&#44; treatment aimed at the sensitivity of the isolated microorganisms must be used in patients with recurrent UTI&#46; TMP&#47;SMX is a good option &#40;B-III&#41;&#46; Quinolones must be avoided as empirical therapy &#40;D-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0320"><span class="elsevierStyleLabel">53&#46;</span><p id="par0450" class="elsevierStylePara elsevierViewall">Duration of antibiotic treatment for recurrent UTIs in transplant patients is not well-defined&#46; At least a 6-week treatment period may be recommendable &#40;B-III&#41;&#44; although other authors suggest prolonging treatment more than three months&#46; Indefinite treatment may be evaluated in diabetic patients&#44; patients with a history of UTIs before or soon after transplantation and those receiving high-dose immunosuppressive treatment &#40;equivalent to secondary prophylaxis&#41; &#40;B-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0325"><span class="elsevierStyleLabel">54&#46;</span><p id="par0455" class="elsevierStylePara elsevierViewall">Anatomical changes related with recurrent UTI must be corrected if possible &#40;A-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0330"><span class="elsevierStyleLabel">55&#46;</span><p id="par0460" class="elsevierStylePara elsevierViewall">The use of non-antibiotic therapies&#44; such as cranberry extract&#44; <span class="elsevierStyleSmallCaps">l</span>-methionine&#44; topical estrogens&#44; or topical application of Lactobacillus&#44; could be provided to transplant patients with recurrent UTI &#40;C-II&#41;&#46;</p><p id="par0465" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">What role does UTI play in kidney graft rejection or dysfunction&#63;</span></p></li><li class="elsevierStyleListItem" id="lsti0335"><span class="elsevierStyleLabel">56&#46;</span><p id="par0470" class="elsevierStylePara elsevierViewall">Kidney transplant patients are particularly vulnerable to infections&#44; and this is one of the reasons for which primary prophylaxis has been established &#40;A-I&#41; and early aggressive treatment of symptomatic UTI is recommended &#40;A-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0340"><span class="elsevierStyleLabel">57&#46;</span><p id="par0475" class="elsevierStylePara elsevierViewall">Although UTI has been associated with induction of acute rejection in kidney transplant patients &#40;A-II&#41;&#44; there is controversy about the final impact on the graft in terms of chronic rejection or dysfunction &#40;B-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0345"><span class="elsevierStyleLabel">58&#46;</span><p id="par0480" class="elsevierStylePara elsevierViewall">Late-onset UTIs&#44; which were traditionally associated with a good prognosis&#44; have also been recently related with a risk of rejection or dysfunction of the kidney graft &#40;B-II&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0350"><span class="elsevierStyleLabel">59&#46;</span><p id="par0485" class="elsevierStylePara elsevierViewall">The association between AB and graft loss is unclear&#46;</p><p id="par0490" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Antimicrobial and immunosuppressant interactions</span> &#40;<a class="elsevierStyleCrossRefs" href="#tbl0030">Tables 6&#8211;11</a>&#41;</p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia><elsevierMultimedia ident="tbl0035"></elsevierMultimedia><elsevierMultimedia ident="tbl0040"></elsevierMultimedia><elsevierMultimedia ident="tbl0045"></elsevierMultimedia><elsevierMultimedia ident="tbl0050"></elsevierMultimedia><elsevierMultimedia ident="tbl0055"></elsevierMultimedia></li><li class="elsevierStyleListItem" id="lsti0355"><span class="elsevierStyleLabel">60&#46;</span><p id="par0495" class="elsevierStylePara elsevierViewall">The treatment of UTIs in SOT recipients is more complex due to interactions between antimicrobials and immunosuppressants&#46;</p></li><li class="elsevierStyleListItem" id="lsti0360"><span class="elsevierStyleLabel">61&#46;</span><p id="par0500" class="elsevierStylePara elsevierViewall">The interactions may jeopardize the transplanted organ and also increase the specific adverse effects of each drug&#46;</p></li><li class="elsevierStyleListItem" id="lsti0365"><span class="elsevierStyleLabel">62&#46;</span><p id="par0505" class="elsevierStylePara elsevierViewall">Key measures to avoid the consequences of these interactions are to know and to prevent them by monitoring the plasma levels of these drugs&#44; monitoring graft function and characteristic adverse effects&#44; and avoiding contraindicated combinations &#40;AII&#41;&#46;</p></li></ul></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Conflict of interest</span><p id="par0510" class="elsevierStylePara elsevierViewall">JMC has received a conference grant from <span class="elsevierStyleGrantSponsor" id="gs0005">Astellas</span>&#44; <span class="elsevierStyleGrantSponsor" id="gs0010">Astra-Zeneca</span>&#44; <span class="elsevierStyleGrantSponsor" id="gs0015">MSD</span>&#44; <span class="elsevierStyleGrantSponsor" id="gs0020">Novartis</span>&#44; and <span class="elsevierStyleGrantSponsor" id="gs0025">Pfizer</span>&#46; All other authors have no conflict of interest to declare&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres587771"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec603522"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres587772"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec603521"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Methods"
        ]
        6 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "Definitions"
          "secciones" => array:8 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Bacteriuria"
            ]
            1 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Cystitis"
            ]
            2 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Pyelonephritis"
            ]
            3 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Reinfection"
            ]
            4 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Relapse"
            ]
            5 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Recurrent infection"
            ]
            6 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Complicated urinary tract infection"
            ]
            7 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Prostatitis"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0060"
          "titulo" => "Epidemiology and risk factors for UTI in SOT recipients"
        ]
        8 => array:2 [
          "identificador" => "sec0065"
          "titulo" => "Recommendations"
        ]
        9 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Conflict of interest"
        ]
        10 => array:2 [
          "identificador" => "xack197727"
          "titulo" => "Acknowledgements"
        ]
        11 => array:1 [
          "titulo" => "Reference"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec603522"
          "palabras" => array:5 [
            0 => "Urinary infection"
            1 => "Transplantation"
            2 => "Consensus"
            3 => "Prophylaxis"
            4 => "Treatment"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec603521"
          "palabras" => array:5 [
            0 => "Infecci&#243;n urinaria"
            1 => "Trasplante"
            2 => "Consenso"
            3 => "Profilaxis"
            4 => "Tratamiento"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Urinary tract infections &#40;UTI&#41; are one of the most common infections in solid organ transplant &#40;SOT&#41; recipients&#46; A systematic review was performed to assess the management of UTI in SOT recipients&#46;</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Recommendations are provided on the management of asymptomatic bacteriuria&#44; and prophylaxis and treatment of UTI in SOT recipients&#46; The diagnostic&#8211;therapeutic management of recurrent UTI and the role of infection in kidney graft rejection or dysfunction are reviewed&#46; Finally&#44; recommendations on antimicrobials and immunosuppressant interactions are also included&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Las infecciones del tracto urinario &#40;ITU&#41; son muy frecuentes en los receptores de un trasplante de &#243;rgano s&#243;lido &#40;TOS&#41;&#46; Hemos realizado una revisi&#243;n sistem&#225;tica para determinar el abordaje de la ITU en receptores de TOS&#46;</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Se realizan recomendaciones sobre el abordaje de la bacteriuria asintom&#225;tica y sobre la profilaxis y tratamiento de las ITU en receptores de TOS&#46; Se han revisado el abordaje diagn&#243;stico-terap&#233;utico de las ITU recurrentes y el papel de la ITU en el rechazo o disfunci&#243;n del injerto renal&#46; Finalmente&#44; se incluyen recomendaciones sobre las interacciones entre antimicrobianos e inmunosupresores&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:3 [
        "etiqueta" => "&#9674;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0075">Coordinators of the document&#46; These authors contributed equally to this work&#46;</p>"
        "identificador" => "fn1"
      ]
    ]
    "multimedia" => array:11 [
      0 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Category&#44; grade&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Definition&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Strength of recommendation</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Solid evidence of efficacy and clinical benefit&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Solid or moderately solid evidence of efficacy&#44; but clinical benefit is limited&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Insufficient evidence of efficacy or possible benefits in terms of efficacy do not outweigh the cost or risks &#40;toxicity and drug interactions&#41;&#44; valid alternatives are available&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>D&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderately solid evidence of a lack of efficacy or poor outcome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>E&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Strong evidence of a lack of efficacy or poor outcome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Quality of evidence</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>I&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Evidence from at least 1 well-designed and performed trial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Evidence from at least 1 well-designed non-randomized clinical trial&#44; cohort study&#44; or a non-controlled experimental study with non-conclusive results&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Expert opinion based on clinical experience&#44; descriptive studies&#44; or reports from expert panels&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959789.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Classification of the recommendations of this consensus document based on the strength and quality of the evidence analyzed&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Stamey T&#46; Pathogenesis and Treatment of Urinary Tract Infections&#46; Baltimore&#58; Williams &#38; Wilkins&#59; 1980&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sample&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Symbol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Description&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Bladder emptying 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">BE<span class="elsevierStyleInf">1</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Initial 5&#8211;10<span class="elsevierStyleHsp" style=""></span>ml of urine stream&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Bladder emptying 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">BE<span class="elsevierStyleInf">2</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sample midstream urinary&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Expressed prostatic secretions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">EPS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Secretions obtained from transrectal prostate by digital massage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Bladder emptying 3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">BE<span class="elsevierStyleInf">3</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">First 5&#8211;10<span class="elsevierStyleHsp" style=""></span>ml of urine stream immediately after prostatic massage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959782.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Definitive diagnosis of bacterial prostatitis requires that the number of colonies in the BE<span class="elsevierStyleInf">3</span> sample exceeds those in the BE<span class="elsevierStyleInf">1</span> sample&#44; preferably by more than 10 times&#46; However&#44; the prostate of many patients with chronic prostatitis contains only small amounts of bacteria&#46; In these patients&#44; a prostatic secretions culture is particularly useful&#46; Microscopic examination of the EPS is useful to identify leukocytes and &#8220;oval fat bodies&#8221; &#8211; large lipid-laden macrophages characteristic of prostatic inflammatory response&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Sequential urine cultures for anatomical location within the lower urinary tract&#46;<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a></p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Female gender&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Age&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Mycophenolate mofetil&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Antithymocyte globulin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Need for immediate post-transplant dialysis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Ureteral stent placement &#62;30 days&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Diabetes mellitus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Deceased-donor kidneys&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Number of episodes of acute rejection&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Reflux kidney disease prior to transplantation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Length of hospitalization&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Length of urinary catheterization&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Number of episodes of acute rejection&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Post-transplant urinary obstructions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Increase in immunosuppression&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959787.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Risk factors for urinary tract infections in solid organ transplantation&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">In all cases&#44; once culture susceptibility results are available&#44; complete therapy with the most narrow-spectrum antibiotic available&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Clinical presentation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Absence of risk factors for multidrug-resistant &#40;MDR&#41; organisms&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Presence of risk factors for MDR organisms<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Cystitis<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fosfomycin or amoxicillin&#47;clavulanate or second&#47;third generation oral cephalosporins&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fosfomycin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">If recurrence is suspected&#44; consider potential infection for MDR organisms&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Alternative therapies</span>&#58; ertapenem&#44; pivmecillinam if available&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Alternative therapy</span>&#58; TMP&#47;SMX or ciprofloxacin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Acute uncomplicated pyelonephritis<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ceftriaxone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ertapenem or piperacillin-tazobactam&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Alternative therapy</span>&#58; amoxicillin&#47;clavulanate or aztreonam &#40;if beta-lactam allergy&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Alternative therapies</span>&#58; aztreonam<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>vancomycin &#40;if beta-lactam allergy&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Severe sepsis&#47;septic shock&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Meropenem<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>vancomycin &#40;if risk factors for enterococcal infection&#41;<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>amikacin &#40;if risk factors for <span class="elsevierStyleItalic">P&#46; aeruginosa</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Meropenem<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>vancomycin&#47;linezolid &#40;if risk factors for enterococcal infection&#41;<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>amikacin &#40;if risk factors for <span class="elsevierStyleItalic">P&#46; aeruginosa</span>&#41;If potential infection by extensively-drug resistant &#40;XDR&#41; <span class="elsevierStyleItalic">P&#46; aeruginosa</span> or carbapenem-resistant <span class="elsevierStyleItalic">Enterobacteriaceae</span> or MDR <span class="elsevierStyleItalic">A&#46; baumannii</span>&#44; consider expert consultation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Alternative therapies</span>&#58; aztreonam<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>vancomycin<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>amikacin &#40;if risk factors for <span class="elsevierStyleItalic">P&#46; aeruginosa</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Alternative therapies</span>&#58; aztreonam&#47;colistin<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>vancomycin&#47;linezolid &#40;if risk factors for enterococcal infection&#41;<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>amikacin &#40;if risk factors for <span class="elsevierStyleItalic">P&#46; aeruginosa</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959785.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Dysuria&#44; urgency&#44; frequency&#44; suprapubic pain without fever&#44; and presence of a urine bacteria count &#62;10<span class="elsevierStyleSup">5</span><span class="elsevierStyleHsp" style=""></span>cfu&#47;ml&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Fever&#44; chills&#44; flank&#47;allograft pain&#44; and presence of a urine bacteria count &#62;10<span class="elsevierStyleSup">5</span><span class="elsevierStyleHsp" style=""></span>cfu&#47;ml&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Prior hospitalization &#40;within 3 months&#41;&#44; previous antibiotic therapy &#40;within 1 month&#41;&#44; previous colonization by MDR organisms&#44; reoperation&#44; nosocomial infection&#44; post-transplant hemodialysis&#44; and nephrostomy&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Empirical treatment of urinary tract infections in solid organ transplant recipients&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "tbl0025"
        "etiqueta" => "Table 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Agent&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Indications&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Dose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Comments&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Fluconazole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Drug of choice for <span class="elsevierStyleItalic">Candida</span> cystitis and pyelonephritis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Loading dose 12<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#44; followed by 6<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;d IV or PO &#40;&#8805;400<span class="elsevierStyleHsp" style=""></span>mg&#47;d for symptomatic candiduria&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Hepatotoxicity in patients with liver insufficiency&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Antifungal prophylaxis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Not recommended in patients with renal replacement therapy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Preemptive therapy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Adjust dose if renal failure and systemic candidiasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Targeted therapy for systemic candidiasis caused by susceptible strains in stable patients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Drug interactions&#58; warfarin&#44; coumadin&#44; oral contraceptives&#44; benzodiazepines&#44; cyclosporine&#44; rifampicin&#44; tacrolimus and others&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">d-AMB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Very rarely needed&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Parenteral 0&#46;3&#8211;1<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;d&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Renal insufficiency&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Symptomatic cystitis or pyelonephritis in patients not responding to or not treatable with fluconazole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Continuous or intermittent bladder irrigation&#58; 50<span class="elsevierStyleHsp" style=""></span>mg in 1<span class="elsevierStyleHsp" style=""></span>L &#40;50<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;ml&#41; 1-7d&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Bladder irritation&#46; Cumbersome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Drug interactions&#58; cisplatin&#44; pentamidine&#44; aminoglycosides&#44; cyclosporine&#44; corticoids and others&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Candins&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Initial drugs of choice for systemic candidiasis in unstable patients&#44; in patients who have been exposed to azoles in the previous 3 months and in patients with renal insufficiency requiring external replacement therapy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Anidulafungin 200<span class="elsevierStyleHsp" style=""></span>mg&#47;d loading dose&#44; followed by 100<span class="elsevierStyleHsp" style=""></span>mg&#47;d&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Preferred if recent azole exposure&#44; patients in septic shock or with external renal devices&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Candida</span> pyelonephritis in patients not responding to or not treatable with fluconazole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Micafungin 100<span class="elsevierStyleHsp" style=""></span>mg&#47;d IV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Low urine concentration&#46; Relapse may occur if the collecting system is the source of the candidemia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Caspofungin 70<span class="elsevierStyleHsp" style=""></span>mg loading dose&#44; followed by 50<span class="elsevierStyleHsp" style=""></span>mg&#47;d IV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Drug interactions&#58; Anidulafungin &#40;none&#41;&#44; Micafungin &#40;sirolimus&#44; nifedipine&#44; itraconazole&#41;&#44; Caspofungin &#40;cyclosporine&#44; tacrolimus&#44; efavirenz&#44; nevirapine&#44; rifampicin&#44; dexamethasone&#44; phenytoin&#44; carbamazepine&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">L-AMB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Candida</span> pyelonephritis in patients not responding to or not treatable with fluconazole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;d IV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Low urine and kidney concentration&#46; Relapse may occur&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Drug interactions&#58; digoxin&#44; aminoglycosides&#44; cyclosporine and others&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Voriconazole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Candida</span> pyelonephritis in patients not responding to or not treatable with fluconazole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;d two loading doses&#44; followed by 3<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;12<span class="elsevierStyleHsp" style=""></span>h IV or PO&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Low urine concentration&#46; Relapse may occur&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Drug interactions&#58; rifabutin&#44; rifampicin&#44; methadone&#44; ritonavir&#44; efavirenz&#44; carbamazepine&#44; ranitidine&#44; macrolides&#44; sirolimus&#44; cyclosporine&#44; tacrolimus&#44; warfarin&#44; coumadin&#44; statins&#44; benzodiazepines&#44; omeprazole&#44; oral contraceptives and others&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Monitor serum levels&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">5-flucytosine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Symptomatic cystitis in patients not responding to or not treatable with fluconazole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25<span class="elsevierStyleHsp" style=""></span>mg&#47;kg every 6<span class="elsevierStyleHsp" style=""></span>h 7&#8211;10 d&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Emergence of resistance if given alone or for prolonged periods&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Adjust dose if renal insufficiency&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Gastrointestinal&#44; liver and bone marrow toxicity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959786.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Antifungal drugs&#46;</p>"
        ]
      ]
      5 => array:7 [
        "identificador" => "tbl0030"
        "etiqueta" => "Table 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">AMK&#58; amikacin&#59; GEN&#58; gentamicin&#59; ETM&#58; streptomycin&#59; EPT&#58; spectinomycin&#59; KAN&#58; kanamycin&#59; TOB&#58; tobramycin&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">AMK&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">GEN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ETM&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">EPT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">KAN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TOB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Cyclosporine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Tacrolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Mycophenolate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Sirolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Everolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Azathioprine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Prednisone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Basiliximab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Muromonab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959788.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0025"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0025">A&#47;a&#58; these drugs should not be co-administered&#59; B&#47;b&#58; potential interaction &#8211; may require monitoring of plasma levels and graft function and&#47;or change in dose&#59; C&#47;c&#58; no clinically relevant interactions&#59; A&#44; B&#44; C&#58; indicate that interaction has been described&#59; a&#44; b&#44; c&#58; indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Interactions between aminoglycosides and immunosuppressants&#46;<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">a</span></a></p>"
        ]
      ]
      6 => array:7 [
        "identificador" => "tbl0035"
        "etiqueta" => "Table 7"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">AMP&#58; ampicillin&#59; AMC&#58; amoxicillin&#8211;clavulanate&#59; CLO&#58; cloxacillin&#59; NAF&#58; nafcillin&#59; CFU&#58; cefuroxime&#59; CFZ&#58; ceftazidime&#59; CFX&#58; ceftriaxone&#59; AZT&#58; aztreonam&#59; IMI&#58; imipenem&#59; TIC&#58; ticarcillin&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">AMP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">AMC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CLO&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">NAF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CFU&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CFZ&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CFX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">AZT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IMI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TIC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Cyclosporine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Tacrolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Mycophenolate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Sirolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Everolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Azathioprine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Prednisone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Basiliximab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Muromonab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959781.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0030"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0030">A&#47;a&#58; these drugs should not be co-administered&#59; B&#47;b&#58; potential interaction &#8211; may require monitoring of plasma levels and graft function and&#47;or change in dose&#59; C&#47;c&#58; no clinically relevant interactions&#59; A&#44; B&#44; C&#58; indicate that interaction has been described&#59; a&#44; b&#44; c&#58; indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Interactions between beta-lactams and immunosuppressants&#46;<a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">a</span></a></p>"
        ]
      ]
      7 => array:7 [
        "identificador" => "tbl0040"
        "etiqueta" => "Table 8"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">CIP&#58; ciprofloxacin&#59; LEV&#58; levofloxacin&#59; MOX&#58; moxifloxacin&#59; NAL&#58; nalidixic acid&#59; NOR&#58; norfloxacin&#59; OFL&#58; ofloxacin&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CIP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">LEV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MOX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">NAL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">NOR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">OFL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Cyclosporine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Tacrolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Mycophenolate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Sirolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Everolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Azathioprine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Prednisone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Basiliximab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Muromonab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959784.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0035"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0035">A&#47;a&#58; these drugs should not be co-administered&#59; B&#47;b&#58; potential interaction &#8211; may require monitoring of plasma levels and graft function and&#47;or change in dose&#59; C&#47;c&#58; no clinically relevant interactions&#59; NA&#58; data not available&#59; A&#44; B&#44; C&#58; indicate that interaction has been described&#59; a&#44; b&#44; c&#58; indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Interactions between quinolones and immunosuppressants&#46;<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a></p>"
        ]
      ]
      8 => array:7 [
        "identificador" => "tbl0045"
        "etiqueta" => "Table 9"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">TIG&#58; tigecycline&#59; VAN&#58; vancomycin&#59; DAP&#58; daptomycin&#59; LIN&#58; linezolid&#59; COT&#58; cotrimoxazole&#59; DOX&#58; doxycycline&#59; FOS&#58; fosfomycin&#59; CLI&#58; clindamycin&#59; MET&#58; metronidazole&#59; FID&#58; fidaxomicin&#46;</p><p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">NA&#58; Not analyzed&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TIG&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">VAN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">DAP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">LIN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">COT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">DOX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">FOS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CLI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">FID&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Cyclosporine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Tacrolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Mycophenolate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Sirolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Everolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Azathioprine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Prednisone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Basiliximab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Muromonab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959783.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0040"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0040">A&#47;a&#58; these drugs should not be co-administered&#59; B&#47;b&#58; potential interaction &#8211; may require monitoring of plasma levels and graft function and&#47;or change in dose&#59; C&#47;c&#58; no clinically relevant interactions&#59; NA&#58; data not available&#59; A&#44; B&#44; C&#58; indicate that interaction has been described&#59; a&#44; b&#44; c&#58; indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Interactions between other antibiotics and immunosuppressants&#46;<a class="elsevierStyleCrossRef" href="#tblfn0040"><span class="elsevierStyleSup">a</span></a></p>"
        ]
      ]
      9 => array:7 [
        "identificador" => "tbl0050"
        "etiqueta" => "Table 10"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0110" class="elsevierStyleSimplePara elsevierViewall">KET&#58; ketoconazole&#59; ITR&#58; itraconazole&#59; FLU&#58; fluconazole&#59; VOR&#58; voriconazole&#59; POS&#58; posaconazole&#59; CAS&#58; caspofungin&#59; MIC&#58; micafungin&#59; ANI&#58; anidulafungin&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">KET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ITR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">FLU&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">VOR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">POS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CAS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MIC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ANI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Cyclosporine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0050"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0050"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0055"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Tacrolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">d</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">d</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">d</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Mycophenolate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Sirolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B<a class="elsevierStyleCrossRef" href="#tblfn0065"><span class="elsevierStyleSup">e</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Everolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Azathioprine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Prednisone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Basiliximab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Muromonab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959790.png"
              ]
            ]
          ]
          "notaPie" => array:5 [
            0 => array:3 [
              "identificador" => "tblfn0045"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0045">A&#47;a&#58; these drugs should not be co-administered&#59; B&#47;b&#58; potential interaction &#8211; may require monitoring of plasma levels and graft function and&#47;or change in dose&#59; C&#47;c&#58; no clinically relevant interactions&#59; NA&#58; data not available&#59; A&#44; B&#44; C&#58; indicate that interaction has been described&#59; a&#44; b&#44; c&#58; indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0050"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0050">It is recommended to reduce the dose of cyclosporine<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>50&#37;&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0055"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0055">It is recommended to reduce the dose of cyclosporine<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>25&#37;&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0060"
              "etiqueta" => "d"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0060">It is recommended to reduce the dose of tacrolimus<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>33&#37;&#46;</p>"
            ]
            4 => array:3 [
              "identificador" => "tblfn0065"
              "etiqueta" => "e"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0065">It is recommended to reduce the dose of sirolimus<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>50&#37;&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">Interactions between azoles&#44; echinocandins and immunosuppressants&#46;<a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">a</span></a></p>"
        ]
      ]
      10 => array:7 [
        "identificador" => "tbl0055"
        "etiqueta" => "Table 11"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0120" class="elsevierStyleSimplePara elsevierViewall">FUC&#58; flucytosine&#59; ABD&#58; amphotericin B deoxycholate&#59; ABL&#58; liposomal amphotericin B&#59; ABC&#58; amphotericin lipid complex&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">FUC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ABD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ABL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ABC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Cyclosporine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Tacrolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Mycophenolate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Sirolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Everolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Azathioprine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Prednisone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Basiliximab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Muromonab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab959780.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0070"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0070">A&#47;a&#58; these drugs should not be co-administered&#59; B&#47;b&#58; potential interaction &#8211; may require monitoring of plasma levels and graft function and&#47;or change in dose&#59; C&#47;c&#58; no clinically relevant interactions&#59; NA&#58; data not available&#59; A&#44; B&#44; C&#58; indicate that interaction has been described&#59; a&#44; b&#44; c&#58; indicate that interaction is based on a prediction guided by the pharmacokinetic characteristics of the product&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0115" class="elsevierStyleSimplePara elsevierViewall">Interactions between flucytosine&#44; polyenes and immunosuppressants&#46;<a class="elsevierStyleCrossRef" href="#tblfn0070"><span class="elsevierStyleSup">a</span></a></p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Reference"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:1 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of urinary tract infection in solid organ transplant recipients&#58; Consensus statement of the Group for the Study of Infection in Transplant Recipients &#40;GESITRA&#41; of the Spanish Society of Infectious Diseases and Clinical Microbiology &#40;SEIMC&#41; and the Spanish Network for Research in infectious Diseases &#40;REIPI&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Vidal"
                            1 => "C&#46; Cervera"
                            2 => "E&#46; Cordero"
                            3 => "C&#46; Armi&#241;anzas"
                            4 => "J&#46; Carratal&#225;"
                            5 => "J&#46;M&#46; Cisneros"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Enferm Infecc Microbiol Clin"
                        "fecha" => "2015"
                        "volumen" => "33"
                        "paginaInicial" => "679&#46;e1"
                        "paginaFinal" => "679&#46;e21"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack197727"
        "titulo" => "Acknowledgements"
        "texto" => "<p id="par0515" class="elsevierStylePara elsevierViewall">We thank Jes&#250;s Rodr&#237;guez-Ba&#241;o MD&#44; PhD and member of SEIMC for his comments on the manuscript&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/0213005X/0000003300000010/v1_201512110028/S0213005X15001433/v1_201512110028/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "44301"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Documentos de consenso"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/0213005X/0000003300000010/v1_201512110028/S0213005X15001433/v1_201512110028/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X15001433?idApp=UINPBA00004N"
]

Article information

ISSN: 0213005X
Original language: English

DOI:10.1016/j.eimc.2015.03.020

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	12	0	12
2024 October	46	24	70
2024 September	47	22	69
2024 August	44	22	66
2024 July	52	23	75
2024 June	34	8	42
2024 May	31	15	46
2024 April	56	17	73
2024 March	77	15	92
2024 February	37	4	41
2024 January	26	7	33
2023 December	35	8	43
2023 November	55	11	66
2023 October	56	16	72
2023 September	33	4	37
2023 August	31	6	37
2023 July	28	8	36
2023 June	32	12	44
2023 May	28	5	33
2023 April	19	12	31
2023 March	24	12	36
2023 February	21	9	30
2023 January	28	13	41
2022 December	32	15	47
2022 November	46	18	64
2022 October	20	20	40
2022 September	37	18	55
2022 August	49	13	62
2022 July	37	14	51
2022 June	61	13	74
2022 May	107	17	124
2022 April	108	14	122
2022 March	194	14	208
2022 February	223	7	230
2022 January	105	17	122
2021 December	59	19	78
2021 November	114	19	133
2021 October	33	19	52
2021 September	22	21	43
2021 August	31	10	41
2021 July	36	18	54
2021 June	22	14	36
2021 May	30	17	47
2021 April	53	33	86
2021 March	37	18	55
2021 February	32	14	46
2021 January	32	24	56
2020 December	35	22	57
2020 November	31	15	46
2020 October	41	13	54
2020 September	57	25	82
2020 August	57	26	83
2020 July	31	24	55
2020 June	23	20	43
2020 May	37	28	65
2020 April	24	17	41
2020 March	28	11	39
2020 February	53	12	65
2020 January	32	23	55
2019 December	48	24	72
2019 November	46	28	74
2019 October	28	28	56
2019 September	38	22	60
2019 August	40	37	77
2019 July	44	45	89
2019 June	63	52	115
2019 May	133	107	240
2019 April	85	52	137
2019 March	26	16	42
2019 February	28	24	52
2019 January	27	10	37
2018 December	14	9	23
2018 November	23	3	26
2018 October	35	9	44
2018 September	15	9	24
2018 August	10	21	31
2018 July	14	5	19
2018 June	13	4	17
2018 May	22	9	31
2018 April	23	9	32
2018 March	26	7	33
2018 February	22	3	25
2018 January	20	2	22
2017 December	31	1	32
2017 November	39	17	56
2017 October	18	7	25
2017 September	16	17	33
2017 August	17	5	22
2017 July	15	3	18
2017 June	28	25	53
2017 May	22	6	28
2017 April	16	10	26
2017 March	22	29	51
2017 February	17	2	19
2017 January	34	11	45
2016 December	25	3	28
2016 November	30	3	33
2016 October	56	5	61
2016 September	48	13	61
2016 August	30	11	41
2016 July	38	2	40
2016 June	49	14	63
2016 May	30	1	31
2016 April	27	19	46
2016 March	44	37	81
2016 February	28	29	57
2016 January	69	55	124
2015 December	64	75	139

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter